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ABSTRACT
HUMAN MAST CELL TRYPTASE ISOZYMES: SEPARATION AND 
EXAMINATION OF STRUCTURAL AND FUNCTIONAL DIFFERENCES
fay
Susan S. Little
Tryptases are trypsin-like enzymes found in mast cell 
granules. Although in vivo substrates have not been 
positively identified, tryptases cleave a limited number of 
potential physiological substrates in vitro, including high 
molecular weight kininogen (HMWK) and vasoactive intestinal 
peptide (VIP). Purified human lung mast cell tryptase (HLT) 
apparently exists as a tetramer with an M, of 135-144 kDa 
by gel filtration, whereas SDS-PAGE yielded two bands of M, 
29 Kda and 33 Kda. Tryptases are resistant to inhibition by 
most natural trypsin inhibitors and display some affinity 
for heparin. The existence of tryptase isozymes has been 
implied from the cloning of two tryptase cDNAs from human 
lung tissue, but distinct isozymes have not been isolated 
and characterized.
This knowledge gap has been filled by isolating and 
characterizing two electrophoretically different forms of 
human lung mast cell tryptase, designated high-HLT (high 
molecular weight HLT) and low-HLT (low molecular weight 
HLT). These two forms of HLT have been separated by 
chromatography on a cellulose phosphate column, with the 
high M, form eluting with 10 yM heparin and the low M, form 
subsequently eluting with 1 M NaCl. Using HMWK and VIP as 
substrates, these two forms of HLT were found to differ with 
regard to specificity and rate of cleavage. High-HLT 
initially cleaved HMWK at a single Arg residue, whereas low- 
HLT cleaved HMWK simultaneously at multiple sites. Both 
isozymes cleaved VIP at multiple sites, but differed with 
regard to the preferential site of cleavage. Low-HLT was, 
on an active site basis, 25 and 2 times more active than 
high-HLT on HMWK and VIP, respectively. In addition, gel 
filtration of the isozymes yielded M,s of 125 Kda for high- 
HLT and 28 kDa for low-HLT, indicating tetrameric and 
monomeric quaternary structures, respectively. Both 
isozymes were inhibited by human secretory leukocyte 
proteinase inhibitor (SLPI), but not by other trypsin 
inhibitors tested. This work provides the first evidence 
for the existence of distinct tryptase isozymes, with 
supposedly different in vivo functions, and identification 
of an inhibitor that may control tryptase activity in vivo.
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CHAPTER 1 
INTRODUCTION
Over three decades ago, a tryptic-like activity was 
discovered in mast cells by Glenner and Cohen (I960) using 
histochemical techniques. This activity, subsequently named 
tryptase (Lagunoff and Benditt, 1963), has become of 
increasing interest due to the ubiquitous nature and 
biochemical activity of mast cells. Tryptase is a trypsin­
like serine protease found in the cytoplasmic granules of 
most mammalian mast cells and comprises 23% of the total 
cellular protein of human mast cells (Schwartz et al.,
1981a). Tryptases cleave peptide substrates on the carboxyl 
side of Lys and Arg residues but differ from trypsin in that 
they have little or no activity on denatured proteins such 
as casein. Tryptases are stored and released as active 
enzymes (Glenner and Cohen, 1960; Alter et al., 1987), which 
are stabilized by heparin, a component of mast cell granules 
(Smith and Johnson, 1984; Schwartz and Bradford, 1986; Alter 
et al., 1987). Histamine, another major component of mast 
cells, has been used as a specific marker of mast cell 
activation. However, histamine is also found in basophils 
(White et al., 1987), and is cleared more rapidly from the 
site of release than is tryptase (Schwartz et al., 1987a). 
Tryptase has been localized specifically to mast cells 
(Schwartz, 1985; Craig et al., 1986; Schwartz et al., 1985
1
and 1987b) and remains in the vicinity of release longer 
than histamine (Schwartz et al., 1987a) and therefore has 
been proposed as a more specific marker of mast cell 
activation.
Upon mast cell degranulation, tryptase is released 
along with other mediators into the extracellular milieu 
(Schwartz et al., 1981a). The function(s) and regulation 
of tryptase after its release from the cell are not clearly 
understood, but in vitro studies have shown that tryptase 
cleaves several biologically significant molecules. These 
include complement C3 (Schwartz et al., 1983), fibrinogen 
(Schwartz et al., 1985), vasoactive intestinal peptide (VIP) 
(Caughey et al., 1988b; Tam and Caughey, 1990), and high 
molecular weight kininogen (HMWK) (Maier et al., 1983).
Human lung tissue has served as the primary source of 
mast cell tryptase (Smith et al., 1984; Schwartz et al., 
1981a), but other sources include skin (Harvima et al., 
1988b), pituitary (Cromlish et al., 1987) and a human mast 
cell line (Butterfield et al., 1990). In all these cases 
the purified enzyme migrated as two major bands on SDS-PAGE 
with M, differing by about 4,000. Interestingly, purified 
bovine mast cell tryptase also yielded two bands upon SDS- 
PAGE (Fiorucci et al., 1992). These findings have led to 
speculation that the tetramer observed upon gel filtration 
is comprised of two subunits represented by the two species 
seen on SDS-PAGE.
Mast Cells
3
Source and Distribution
Mast cells are derived from bone marrow stem cells, 
migrate through the bloodstream in an immature form and into 
tissues where they differentiate and mature (Barrett and 
Metcalfe, 1987). It is thought that all mast cell subsets 
differentiate from the same precursor cells (Barrett and 
Metcalfe, 1987), but that basophils develop from a distinct 
precursor (Ishizaki et al., 1989). Mast cells are widely 
distributed in the body (Metcalfe et al., 1981) and are most 
numerous at the host-environment interface, such as in the 
intestinal tract, skin and lungs (Malone and Metcalfe,
1988), but are also found along blood vessels and nerves, 
and throughout connective and lymphoid tissues (Metcalfe et 
al., 1981; Friedman and Kaliner, 1987; Bienenstock et al., 
1987; Stead et al., 1987; Bienenstock et al., 1991). In the 
lung, mast cells are most concentrated around the trachea, 
beneath the pleura, and in the connective tissue around 
small airways (Friedman and Kaliner, 1987), although about 
half of the total number of lung mast cells are found in 
peripheral lung tissue (Friedman and Kaliner, 1987).
Morphology
Mast cells are ovoid or irregularly elongated cells of 
about 10-30 pm in diameter with ovoid or round nuclei 
(Metcalfe et al., 1984). The cytoplasm is packed with
4densely-staining granules of 0.1-0.4 ftm diameter (Metcalfe 
et al., 1984), that display a crystalline structure 
appearing as whorls, scrolls, and lattices (Caulfield et 
al., 1980).
IaE Receptors and Deoranulation
The biological activities associated with mast cells 
are the result of the effects of mediators that are released 
into the extracellular milieu upon mast cell activation.
The complex process of mast cell activation culminates in 
the exocytosis of the cytoplasmic granule contents, 
including histamine and tryptase, as well as the production 
and release of newly formed mediators. Mast cells have on 
their surfaces receptors that bind to the Fc portion of 
immunoglobulin E (IgE) molecules (Marom and Casale, 1983). 
There are 1-5 x 10s receptors/roast cell and about 10% of 
these receptors are normally occupied at any given time 
(Metcalfe et al., 1981). Mast cells are most often 
activated by crosslinking (or bridging) of two IgE molecules 
by antigen, which initiates a cascade of events involving 
movement of calcium into the cell, activation of a cell 
membrane associated serine esterase, glycolysis, calcium 
liberation, microtubule assembly, and sequential exocytosis 
of the granules (Kaliner, 1977). However, mast cells can be 
induced to degranulate in response to other stimuli. As 
shown in Figure 1 (Friedman and Kaliner, 1987), a number of
5C hem icals
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Figure 1. schematic illustration of selected mast cell 
secretagogues* This figure was adopted with modifications 
from Friedman and Kaliner (1987).
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6physiological stimuli, such as neuropeptides, 
anaphylatoxins, and histamine-releasing factors from other 
cell types, as well as non-endogenous compounds, such as 
chemicals and drugs, can cause mast cell degranulation*
Even physical stimuli, such as heat, cold and pressure, can 
invoke a mast cell response.
Morphologically, degranulation proceeds through many 
stages including swelling of the granules, decrease in the 
amount of stainable matrix material, disappearance of 
crystalline gratings and lattices, increased visualization 
of scroll patterns, and the appearance of reticular, 
particulate, or flocculent constituents (Caulfield et al., 
1980; Dvorak et al., 1985). The bridging of IgE receptors 
on rat mast cells leads to phospholipid methylation which 
induces, among other things, Ca+a influx and histamine 
release (Ishizaka et al., 1981). There have been two modes 
of release of granule mediators observed: 1) granular 
membranes fuse with other granular membranes and with the 
cellular membrane, forming large channels through which the 
mediators exit the cell (Trotter and Orr, 1973; Trotter and 
Orr, 1974; Hashimoto et al., 1966; Kobayasi and 
Asboe-Hansen, 1969; Orr, 1977; Behrendt et al., 1978); or,
2) no large channels form, with the speculation that 
transient, small pores allow mediators to escape (Galli et 
al., 1984; Berlin and Enerback, 1984; Fernandez et al.,
1984). Degranulation may not result in extrusion of all
granules/granule contents and is not thought to be cytotoxic 
(Friedman and Kaliner, 1985; Friedman et al., 1986; Dvorak 
et al., 1985).
Mast cell Mediators
Three types of mediators have been identified in mast 
cells: 1) those that are preformed and rapidly dissociate 
from the cell upon degranulation; 2) those newly generated 
upon mast cell activation; and 3) those that are preformed 
but do not readily dissociate from the granule. These 
mediators are summarized in Table 1.
Raoidlv Dissociated.Preformed Mediators
Histamine. Histamine (5[2-aminoethyl]-imidazole) is 
stored in the granules of human mast cells (5 ;ig/10* cells) 
in association with heparin proteoglycan, and in human 
basophils (l /xg/106 cells) in association with chondroitin-4 
sulfates, comprising 5-10% of the human mast cell granule by 
weight (White et al., 1987; Wasserman, 1983). Histamine 
diffuses through the tissues rapidly after release and is 
detectable in the bloodstream within minutes of mast cell 
activation (White et al., 1987). Histamine exerts its 
effects through binding to two types of cell surface 
receptors, H, and H2. Binding of histamine to H, receptors 
can cause a variety of effects including smooth muscle 
contraction, increased vascular permeability, an increase in
8Table l. Mast Cell Mediators***
Rapidlv_Dissociated Preformed Mediators 
Histamine
Eosinophil chemotactic factor 
Neutrophil chemotactic factor
Exoglycosidases (0-hexosaminidase, 0-glucuronidase, 0-D- 
galactosidase*)
Arylsulfatase A 
Kininogenase"
Serotonin*
Newlv Generated Mediators
SRS-A: Leukotrienes c, D, and E 
Prostaglandins and thromboxanes 
HETEs 
HPETEs
Platelet activating factor 
Prostaglandin generating factor 
Membrane-bound Preformed Mediators 
Heparin
Neutral proteases: Tryptase and Chymase 
Arylsulfatase B 
Inflammatory factors*
Peroxide*
Superoxide dismutase*
Demonstrated in nonhuman mast cells. ** Kininogenase has 
been determined to be tryptase (Proud et al., 1988; Walls et 
al., 1992). *" Compiled from Marom and Casale, 1983, and
Friedman and Kaliner, 1987.
9cGMP, prostaglandin generation, pruritus, pulmonary 
vasoconstriction, tachycardia, increased nasal mucus 
production and activation of airway vagal afferent nerves 
(White et al., 1987; Wasserman, 1983). Binding of histamine 
to Ha receptors is responsible for an additional group of 
effects including an increase in vascular permeability, 
gastric acid secretion, airway mucus production, and cAMP; 
stimulation of suppressor T-cells; inhibition of skin and 
basophil histamine release and neutrophil chemotaxis and 
enzyme release; and bronchodilatation and esophageal 
contraction (White et al., 1987; Wasserman, 1983). Human 
diseases associated with histamine release and binding 
include asthma, anaphylaxis, urticaria and rhinitis 
(Wasserman, 1983).
chemotactic Factors. Eosinophil chemotactic factors 
(ECF), both high and low molecular weight, serve to attract 
eosinophils and increase eosinophil receptors for complement 
C4 and C3b. Neutrophil chemotactic factors (NCF) attract 
neutrophils and then deactivate them to further chemotactic 
activation by other cells (Wasserman, 1983). There are 
several other less well characterized chemotactic factors in 
mast cells that affect the migration of T and B lymphocytes 
and basophils (Wasserman, 1983).
Acid hydrolases. Acid hydrolases are located primarily 
in lysosomes and function in degradation. Beta-
10
hexosaminidase removes terminal glucosamine residues from 
carbohydrates; fi-glucuronidase removes terminal B- 
glucuronate residues; and arylsulfatases hydrolyze aromatic 
sulfate esters (Wasserman, 1983).
Newly Generated Mediators
Mediators derived from arachidonic acid include slow- 
reacting substances of anaphylaxis (SRS-A), prostaglandins 
(PGs), monohydroxyeicosatetraenoic acids (HETEs), 
hydroperoxyeicosatetraenoic acids (HPETEs), thromboxanes 
(TXs), and platelet activating factor (PAF).
Prostaglandins and Thromboxanes. PGs and TXs are 
derived from arachidonic acid via the cyclooxygenase 
pathway. Chemically, they are c-20 polyunsaturated hydroxy- 
acids with a cyclopentane or oxane ring and they function to 
increase cAMP and cGMP, attract eosinophils and neutrophils, 
and aggregate platelets.
SRS-A. HETE. HPETE and PAF. SRS-A, HETE and HPETE are 
derived from arachidonic acid via the lipoxygenase pathway 
and PAF is an ether analog of phosphatidyl choline. SRS-A 
is made up of the leukotrienes (LT) C, D, and E (6-sulfido- 
ether linked conjugated trienes). The LTs affect mucus 
secretion, while the HETEs and HPETEs affect mediator 
release, increase vascular permeability and vasodilatation, 
inhibit T cell secretion of lymphokines, and inhibit 
lymphokine transformation and lymphocyte-mediated
cytotoxicity (Marom and Casale, 1983). PAF is the most 
potent platelet-aggregating compound known and can cause a 
wide variety of other effects such as augmenting neutrophil 
migration, enzyme release and oxidative metabolism 
(Wasserman, 1983).
Membrane-bound Preformed Mediators
The third type of mediators are not readily dissociated 
from the granule membrane following degranulation and may 
reguire high ionic strength for separation. These include 
heparin, arylsulfatase B and the neutral proteases 
carboxypeptidase, chymase and tryptase.
Heparin. Heparin is a proteoglycan with highly 
sulfated glycosaminoglycan side chains that give it a high 
negative charge density (Wasserman, 1983). Human lung and 
skin mast cells contain about 5 pg of heparin (MW 60 kDa) 
per 106 cells (Metcalfe et al., 1979; Metcalfe et al., 1980; 
Wasserman, 1983). Some of the activities attributed to 
human heparin include binding histamine, inhibiting 
complement activation, acting as an anticoagulant, binding 
platelet factor 4 and binding and stabilizing the activity 
of tryptase (Wasserman and Austen, 1977; Schwartz et al., 
1981b; Smith et al., 1984; Wasserman, 1983). Rat serosal 
mast cells contain about 25 fig of heparin proteoglycan (MW 
750 kOa) per 10fi cells, which can bind histamine and inhibit 
complement activity (Yurt et al., 1977; Weiler et al..
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1978).
Arvlsulfatase B. Arylsulfatase B is a glycoprotein 
that hydrolyzes aromatic sulfate esters and is present in 
rat mast cells and human pulmonary mast cells (Schechter et 
al., 1983).
Carboxypeptidase. Carboxypeptidases isolated from 
mouse (Serafin et al., 1987), rat (Everitt and Neurath, 
1980), and human (Goldstein et al., 1987; Goldstein et al,
1989) mast cells are zinc-dependent metalloexopeptidases 
(Reynolds et al., 1989). There are two classes of mast cell 
carboxypeptidases (MC-CP), designated carboxypeptidase A 
(MC-CPA) and carboxypeptidase B (MC-CPB), that exhibit a 
substrate specificity for carboxy-terminal 
aliphatic/aromatic amino acids and basic amino acids, 
respectively (Reynolds et al., 1989). An MC-CPA has been 
isolated from a subset of human mast cells that contain both 
of the other mast cell neutral proteases, chymase and 
tryptase (Irani et al., 1991). The mature protein contains 
308 amino acids, has a MW of 36.1 kDa, carries a positive 
charge of 16 at neutral pH, and functions to remove carboxy- 
terminal Phe and Leu residues from substrates (Reynolds et 
al., 1989; Irani et al., 1991).
chvmase. chymases and tryptases are the two major 
neutral serine proteases found in the cytoplasmic granules 
of mast cells. Chymases are chymotrypsin-like enzymes that
cleave target proteins on the carboxyl side of hydrophobic 
residues, more specifically Tyr and Phe residues (Craig and 
Schwartz, 1989). They have been isolated from several 
species including rodent (Woodbury and Neurath, 1980), sheep 
(Huntley et al., 1986), dog (Caughey et al., 1988a) and 
human (Schechter et al., 1983). The enzyme is a monomer of 
30 kDa and, like tryptase, is stored in its active form in 
the secretory granules, probably bound to heparin (Schechter 
et al., 1983; Johnson, et al., 1986; Wintroub et al., 1986; 
Sayama et al., 1987). Unlike tryptase, however, chymase is 
inhibited by the plasma proteinase inhibitors alpha-l- 
proteinase inhibitor (a,-PI) and alpha-l-antichymotrypsin 
(at-AC) (Schechter et al., 1989). Human mast cell chymase 
is much more abundant in skin mast cells than in lung mast 
cells (Schechter et al., 1983; Schechter et al., 1986).
Human skin chymase is similar to RMCP I (rat chymase) and 
dog skin chymase in its activity on synthetic substrates 
(Powers et al., 1985). Chymases have been observed to 
convert angiotensin I to angiotensin II (a vasoconstrictor) 
in vitro and to inactivate bradykinin and kallidin, two 
vasodilators, suggesting a role in initiating or 
perpetuating vasoconstriction (Reilly et al., 1982; Reilly 
et al., 1985; Wintroub et al., 1984). Chymase also cleaves 
VIP (a bronchodilator), substance P (a potent 
bronchoconstrictor and mast cell activator), and calcitonin 
gene-related peptide (CGRP) (a potent vasodilator and
bronchoconstrictor) (Brain et al., 1985; Palmer et al.,
1987; Franconi et al., 1989), further indicating a role in 
the control of vasoactive peptides (Brain and Williams,
1988; Caughey et al., 1988b). Data has also been produced 
indicating that chymase is a very potent secretagogue for 
airway serous cells (Sommerhoff et al., 1989), supporting a 
role for chymase in airway hypersecretion.
Tryptase. Tryptases have been isolated from a number 
of species, including human (Schwartz et al., 1981a; Smith 
et al., 1984; Cromlish et al., 1987; Harvima et al., 1988b), 
dog (Caughey et al., 1987; Schechter et al., 1988), rat 
(Kido et al., 1985a) and bovine (Fiorucci et al., 1992). 
Although tryptases in general are 40% identical to trypsin 
in amino acid sequence, they differ from trypsin and each 
other in several ways. Unlike trypsin, tryptases are not 
inhibited by plasma proteinase inhibitors, such as a,-PI and 
alpha-2-macroglobulin (a3M), or other trypsin inhibitors, 
like bovine pancreatic trypsin inhibitor (BPTI), soybean 
trypsin inhibitor (SBTI) and lima bean trypsin inhibitor 
(LBTI) (Schwartz et al., 1981b; Smith et al,, 1984; Cromlish 
et al., 1987). Whereas trypsin cleaves proteins such as 
casein and albumin, tryptases are not active on most 
proteins. Also unlike trypsin, human tryptases, both lung 
(Schwartz et al., 1981a; Smith et al., 1984) and skin 
(Harvima et al., 1988a), have been reported to exist as
te trainers, bind heparin, and show reduced activity with 
increasing NaCl concentrations. Dog tryptase (Caughey et 
al., 1987; Schechter et al., 1986), rat tryptase (Kido et 
al., 1985a; Braganza and Simmons, 1991), and bovine tryptase 
(Fiorucci et al., 1992) displayed similar, although not 
identical, characteristics. Dog tryptase was inhibited by 
BPTI; rat tryptase did not bind heparin and was inhibited by 
several of the low molecular weight trypsin inhibitors, 
specifically o,-PI, SBTI, BPTI, and trypstatin, an 
endogenous inhibitor co-localized in rat mast cell granules 
(Kido et al., 1988); and bovine tryptase formed oligomers of 
360 kDa (subunit sizes of 39 and 41 kDa) and was inhibited 
by BPTI, which is actually made in mast cells (Fritz et al.,
1979) .
While tryptase is a poor protease in that there are 
very few known natural substrates, there are several 
molecules that are known to be cleaved by tryptase. Of 
particular note are vasoactive intestinal peptide (VIP) 
(Caughey et al., 1988b; Tam and Caughey, 1990), and high 
molecular weight kininogen (HMWK) (Maier et al., 1983).
HMWK is a plasma protein that participates in 
coagulation by contributing to the activation of Factor XII 
at the beginning of the intrinsic pathway (Movat, 1979). 
Cleavage of HMWK by kallikrein releases bradykinin, a 
nonapeptide, causing pain, increased vascular permeability, 
and bronchoconstriction (Webster, 1970). Human lung
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tryptase destroyed the procoagulation function of HMWK, 
which supports a possible role for tryptase in 
anticoagulation, but did not release bradykinin (Maier et 
al., 1983). While it was likely that tryptase inactivated 
the procoagulant function of HMWK via cleavage in the C- 
terminal region, the exact cleavage site was not determined.
VIP is a 28 amino acid neuropeptide that acts as a 
potent relaxant of human bronchial and vascular smooth 
muscle (Barnes et al., 1984; Morice et al., 1984). Mast 
cells in the lung are in close proximity to nerves 
controlling bronchial muscle tone (Stead et al., 1987), 
which led Tam and Caughey (1990) to examine the effect of 
human lung tryptase on VIP. They found that tryptase 
degrades VIP by cleaving it in several positions, possibly 
resulting in a local deficiency of VIP's bronchial relaxant 
activity, which may be a contributing factor to asthma-like 
symptoms (Said, 1984).
Complement C3, another reported tryptase substrate, is 
cleaved to produce the anaphylatoxin C3a, which causes 
smooth muscle contraction and increased vascular 
permeability (Schwartz et al., 1983). Fibrinogen, which in 
vivo is a substrate for thrombin and a precursor to fibrin 
in the blood coagulation cascade, lost all clotting ability 
after being cleaved by tryptase in vitro (Schwartz et al.,
1985). These data suggest possible tryptase involvement in 
anticoagulation, the immediate hypersensitivity response,
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and bronchial smooth muscle contraction in asthma-like 
conditions.
Other substrates cleaved by tryptases include pro- 
atrial natriuretic factor (pro-ANF) (imada et al., 1987 and 
1988; Seidah et al., 1986; Proctor et al., 1991; Wypij and 
Harris, 1988) to produce ANF, a potent diuretic, natriuretic 
and hypotensive (DeBold, 1985); peptide histidine-methionine 
(PHM), a potent bronchodilating peptide, and CGRP, a potent 
vasodilator and bronchoconstrictor (Tam and Caughey, 1990); 
kinetensin, a peptide isolated from pepsin-treated human 
plasma that shares homology with neurotensin and angiotensin 
(Mogard et al., 1986; Goldstein et al., 1991); prothrombin 
to thrombin (Kido et al., 1985b; Dietze et al., 1990); and 
synovial procollagenase and/or pro-stromelysin (Gruber et 
al., 1988; Gruber et al., 1989) to produce stromelysin and 
collagenase, which degrade proteoglycans, fibronectin, 
laminin, type IV and type IX collagen, and gelatin (Sellers 
et al., 1978; Harris et al., 1984; Okada et al., 1986). 
Johnson and Cawston (1985) reported that tryptase was not a 
direct activator of procollagenase. Gruber et al. (1988) 
later reported that tryptase was an activator of 
procollagenase, but subsequently (Gruber et al., 1989) 
reported that tryptase only activated prostroraelysin which 
then activated procollagenase, confirming the original data 
of Johnson and Cawston. These data suggest that tryptase 
could be involved in the control of fluid volume and blood
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pressure control (Wypij and Harris, 1988), bronchial tone 
(Taro and Caughey, 1990) and contribute to matrix degradation 
in rheumatoid arthritis (Gruber et al., 1989). There is a 
conflicting report about the ability of human tryptase to 
cleave prothrombin (Harvima et al., 1989), leaving doubt as 
to its potential procoagulant activity. Most of these 
substrate studies were performed in vitro and ,therefore, 
their in vivo significance is unclear.
To investigate the underlying structural features of 
tryptase responsible for the tendency to form 
tetramers/oligomers and for the seeming unavailability of 
the active site for interaction with protein substrates and 
inhibitors, Johnson and Barton (1992) performed computer 
molecular modelling studies based on the structure of bovine 
trypsin. Their data showed two large insertions on either 
side of the substrate binding pocket that may limit access 
of many substrates and inhibitors to the active site. 
Additionally, two hydrophobic patches unique to the 
tryptases were apparent on the models and may contribute to 
tetramer formation and/or interaction with other hydrophobic 
molecules such as membranes.
in experimental studies previously performed, the human 
lung roast cell tryptase preparations used may have contained 
one or more isozymic forms. Two different tryptase cDNAs 
have been cloned from a human lung tissue library (Miller et 
al., 1989; Miller et al., 1990) and three from a human Bkin
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cDNA library (Vanderslice et al., 1990), one of which was 
identical to one of the lung cDNAs. A dog tryptase has been 
cloned from dog mastocytoma cells (Vanderslice et al., 1989) 
and two mouse tryptases have been cloned from a mouse mast 
cell line (chu 1990; Reynolds et al., 1991; McNeil et al., 
1992). The amino acid sequences derived from these cDNAs 
are shown aligned with trypsin and chymotrypsin in Figure 2. 
The coding regions of all of the tryptases are 244 or 245 
amino acids in length with one or two putative N-linked 
glycosylation sites (Asn-Xaa-Thr/Ser). The human tryptases 
show >90% sequence identity to each other and 73-78% 
identity to dog tryptase whereas the two mouse tryptases 
share only 70% identity to each other. A high degree of 
homology between all the tryptases in an 11 amino acid 
propeptide is also observed. The propeptide is unusual in 
that it ends in a Gly residue, which is unique among the 
serine proteases and suggests a novel mode of activation 
(Vanderslice, 1989). All of the tryptases have an Asp 
residue in the proposed base of the substrate binding 
pocket, conferring the preference of tryptase for substrates 
having Lys or Arg at the PI position. Multiple cDNAs 
isolated from humans and evidence of multiple tryptase genes 
(Vanderslice, 1990) suggest the existence of multiple active 
forms of the enzyme.
Mast Cell Heterogeneity
It should be noted that not all mast cells produce
Figure 2
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equivalent amounts of the various mediators, even within the 
same individual. For example, mast cells from human lung 
released a much higher amount of histamine and leukotrienes 
D4 and E4 than those from human foreskin (Church et al.,
1989). Varying amounts of the neutral proteases tryptase 
and chymase have led to a proposed system of nomenclature 
for human mast cells based on the presence or absence of 
these two enzymes. Hast cells containing tryptase but no 
chymase have been labeled T mast cells (MCf), while mast 
cells containing both tryptase and chymase have been labeled 
TC mast cells (HC^) (Irani et al., 1986). Ninety percent 
of the total number of mast cells found in human pulmonary 
tissue and 98% in intestinal mucosa were the T type, whereas 
the TC type accounted for 88% of mast cells in human skin 
and 87% in intestinal submucosa (Irani et al., 1986). It 
has been determined that T mast cells contain approximately
10.8 pg of tryptase per cell while TC mast cells contain 
approximately 35 pg of tryptase and 4.5 pg of chymase per 
cell (Schwartz et al., 1987c).
Rat mast cells have been categorized as either mucosal 
or connective tissue type based primarily on location and 
the type of chymotrypsin-like enzyme present. Connective 
tissue type mast cells contain a chymase called rat mast 
cell protease I (RMCP I) (Yurt and Austen, 1977; Seppa and 
Jarvinen, 1978; Woodbury et al., 197Ba) and mucosal type 
mast cells contain a chymase called RHCP II (Woodbury et
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al., 1978b). The physiological significance of mast cell 
heterogeneity between tissues is not clearly understood.
Pathogenesis of Mast, cells
Mast cells are thought to participate in normal 
homeostasis by contributing to: resistance to parasitic 
infestation {Miller and Jarrett, 1971; Haig et al., 1984; 
Capron et al., 1978), wound healing (Matsuda and Kitamura, 
1981), angiogenesis (Azezthan et al., 1980; Kessler et al., 
1976), and tumor immunity (Henderson et al., 1981; Farram 
and Nelson, 1980). They have also been implicated in a 
number of pathological conditions, including anaphylaxis 
(Austen, 1974), asthma (Crisp et al., 1984; Godfrey et al.,
1984), inflammatory bowel disease (Dvorak et al., 1980; 
Barrett and Metcalfe, 1984), and rheumatoid arthritis 
(Wasserman, 1984). The symptoms in these disease states 
range from acute and life-threatening to chronic and 
debilitating. It is apparent from the above information 
that the basic biochemical functions of mast cells and their 
mediators in health and disease are varied and complex, and 
an understanding of them is crucial in the guest to maintain 
or restore health.
Project Objectives and Overview 
In spite of the knowledge of multiple cDNAs and genes 
for human tryptase, there is no information concerning 
possible functional differences between the various forms of
tryptase, neither has it been possible to correlate 
different electrophoretic forms with cDNA sequences. This 
project was designed to fill these knowledge gaps by 
isolating human tryptase isozymes, which could then be 
compared with regard to structure and function.
Two forms of the human lung tryptase, differing in 
molecular weight, were partially separated by 
chromatographic techniques and were shown in this laboratory 
to be independently active (smith et al., 1984). Starting 
with human lung tissue, two forms of active tryptase have 
been isolated, which are designated high-HLT (high molecular 
weight human lung tryptase) and low-HLT (low molecular 
weight human lung tryptase). These two isozymes have been 
examined, and in some cases compared, with respect to their 
structural and functional characteristics in an attempt to 
confirm the existence of two independently active tryptases 
in human lung, to partially define those differences, and to 
determine their relationship to the previously discussed 
cDNAs cloned from human lung mast cells.
CHAPTER 2 
MATERIALS AND METHODS
Materials
Frozen human lung tissue was procured through the 
National Disease Research Interchange. Cellulose phosphate 
(fibrous form), cetylpyridinium chloride, porcine heparin 
(ammonium salt, average MW = 10,000), DTNB, Cbz-Lys-SBzl, 
Brilliant Blue G Colloidal Concentrate, fish gelatin, 
trichoroacetic acid, TFA, and Amino Acid Standard solution 
(#A97B1) were purchased from Sigma Chemical Company. MES, 
NaCl, NaNj, glycerol, HEPES, Brij 35, DMSO, HN03, enzyme 
grade sodium acetate trihydrate, HPLC grade acetonitrile 
were products of Fisher Scientific. Enzyme grade ammonium 
sulfate was purchased from ICN Biomedicals. Spectra/Por 
standard dialysis tubing (4.5 cm; 12,000-14,000 MWC0) was a 
product of Spectrum Medical Industries, Inc. Absolute (200 
proof) ethanol was a product of AAPER Alcohol & Chemical Co. 
HPLC grade triethylamine was purchased from Pierce Chemical 
Co. Copper Stain & Destain Kit was purchased from Bio-Rad 
Laboratories. Toyopearl Butyl 650-M hydrophobic interaction 
chromatography column material was purchased from TosoHaas, 
Sephacryl S200-HR gel filtration column material was 
purchased from Pharmacia. VIP was purchased from Bachem, 
Inc. Recombinant N-Glycanase was purchased from Genzyme. A 
glass-lined, 300A pore, Nucleosil C„, HPLC column (4mm x
24
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250mm) was purchased from SGE. Pico-tag C„ column and 
Immobilon-P PVDF membrane were purchased from Millipore and 
PVDF-Plus Transfer Membrane was obtained from MSI,
NH^acetate, purchased from Mallinckrodt, was kindly provided 
by Dr. M.-L. Ernst-Fonberg. SLPI was kindly provided by Dr. 
R. Thompson (Synergen, Boulder, CO). Arg15Glu51aprotinin was 
graciously provided by Dr. H. Fritz (Univ. of Munich,
Munich, Germany). ASTI was the kind gift of Dr. R. Peanasky 
(Univ. of s. Dakota, Vermillion, SD). Ial was the kind gift 
of Dr. J. Enghild (Duke Univ., Durham, NC). APPI was kindly 
provided by Dr. T. Hynes (Genentech, Inc., San Francisco,
CA). Ecotin was the kind gift of Dr. M. McGrath (Univ. of 
California at San Francisco, SF, CA). CMTI-III was kindly 
provided by Dr. c. McWherter (Monsanto, St. Louis, MO). 
Protein G Gold Immun-blot Assay Kit, purchased from Bio-Rad, 
was kindly provided by Dr. J. Suttles. Monoclonal 
antibodies to the light chain of HMWK were graciously 
furnished by Dr. A. Schmeier (University of Michigan, Ann 
Arbor). Laminin, plasminogen-free fibrinogen, and 
fibronectin were the kind gifts of Dr. S. Stack (Duke 
University, Durham,NC). Fresh frozen human blood plasma was 
obtained from the American Red Cross. All other reagents 
were ACS grade unless otherwise specified.
Trvotase Activity Assay
Enzyme activity was monitored using the substrate Cbz-
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Lys-SBzl, which when hydrolyzed produces a free thiol that 
reacts with DTNB to produce a yellow color. The chemical 
reaction involved is shown helow:
One unit of activity was defined as the amount of enzyme 
needed to produce an increase in absorbance at 410 nm (A4I0) 
of 1.0/minute. Specific activity was defined as the 
increase in A^/minute/ml divided by the A3I0. An appropriate 
amount of enzyme was added to 0.1 M HEPES, 10 pK heparin 
(100 /ig/ml), 10% glycerol, 0.05% Brij 35, 0.02% NaNJ( pH 7.5 
(assay buffer) containing 1 mM DTNB for a total volume of 
980 /il. Assays were started by adding 20 nl of 20 mM Cbz- 
Lys-SBzl in DMSO for a final volume of 1 ml (final substrate 
concentration equaled 0.4 mM) and the change in A410/minute 
was monitored for 3 minutes at room temperature in a Beckman 
DU-30 spectrophotometer using the kinetics data program on 
the Beckman Kinetics cartridge, chromatography fractions 
were assayed using a microtiter plate reader and 96-well 
microtiter plates with the assay incubation mixture reduced
C bz-L ys-S B zl— >  C bz-Lys-C O , + HSBz]
Tryptase
Yellow
C olor
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proportionately to 200/il.
Tryptase Purification
Frozen human lung tissue (500 g) was cut into small 
pieces and disrupted in a Waring blender with 500 ml of cold 
distilled HjO for 10-15 seconds. The homogenate was 
centrifuged at 25,400 x g for 20 min. in a Beckman J-21C 
centrifuge at 5°C and the supernatant was discarded. The 
blending and centrifuging process was repeated using cold 20 
mM MES with 0.15 M NaCl and 0.02% NaN3 at pH 6.1 in place of 
dH20 until supernatant fractions were visibly free of 
hemoglobin. Tryptase activity was extracted from the tissue 
by repeating the blending and centrifuging process four 
times using 500 ml of cold 20 mM MES 2 M NaCl 0.02% NaN3 pH 
6.1 each time* The viscosity of the crude extract was 
reduced by removing the lipid present; this involved adding 
an equal volume of 2% cetylpyridinium chloride in lOmM MES 
0.02% NaNj pH 6.1 and incubating at room temperature for 30 
minutes followed by centrifugation at 25,400 x g (5°C) for 
60 minutes. The extract was then made 2 M in (NH4)2S04, 
centrifuged as above, and filtered through glass wool. This 
filtrate was mixed with 50 ml of Toyopearl Butyl 650-M 
column material equilibrated with 10 mM MES, 0.5 M NaCl, 2 M 
(NH4)2S04, 20% glycerol, 0.02% NaN3, pH 6.1 and incubated at 
room temperature for 45 minutes. This mixture was 
centrifuged at 5860 x g (5°C) and the supernatant containing
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unbound proteins was decanted and tested for activity. The 
column material with bound tryptase was collected by 
centrifugation/ the slurry was poured into a chromatography 
tube (2.2 x 12 cm) and washed extensively with equilibration 
buffer. All of the tryptase activity bound to the column 
material and was subsequently eluted with a 250 ml linear 
gradient of decreasing ionic strength from 2.0 to 0.0 H 
(NH4)3S04, collecting 2 ml fractions at one minute intervals. 
The active fractions were pooled/ made 0.05% in Brij 35, and 
dialyzed against 4 liters of 10 mM MES, 0.3 M NaCl, 0.02% 
NaN3, pH 6.1 for 3 hours at 4°C, followed by dialysis 
against 4 liters of the same buffer containing 20% glycerol 
for 3 hours. This pool was then loaded onto a 20 ml 
cellulose phosphate column equilibrated with the last 
dialysis buffer. After washing with equilibration buffer, 
one of two elution profiles was used. Either high-HLT was 
eluted first with 10 jxM heparin in equilibration buffer, 
followed by elution of low-HLT with 1 M NaCl in 
equilibration buffer, or a gradient of 0.3 M to 1.5 M NaCl 
and 0 to 50 /*M heparin in equilibration buffer was used to 
elute both isozymes, with the high-HLT eluting first. The 
total gradient volume was 150 ml and 1 ml fractions were 
collected at 1 ml/minute for both elution profiles. The 
overall recovery of activity was usually about 25% with the 
high M, fraction representing approximately 85% of the total 
and the low M, form accounted for 15% of the activity on
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Cbz-Lys-SB2l. The active fractions from each peak were 
pooled and analyzed by SDS-PAGE.
Electrophoresis
SDS-PAGE analysis of proteins or cleavage products was 
carried out under reducing conditions on 1.5 nun thick 6%, 8% 
or 10% polyacrylamide gels as described by Bury (1981). 
Proteins were stacked at 15 mA and the current was increased 
to 20 mA after the dye front entered the separating gel.
The gels were placed in MetOH/acetic acid/H20 (40%/7%/53% 
v/v) to fix the proteins in the gels, stained with colloidal 
Coomassie Brilliant Blue and destained with MetOH/acetic 
acid/H20 (25%/l0%/65% v/v) for 30 seconds followed by 
Met0H/H20 (25%/75% v/v) until the background stain 
disappeared.
Electroelution of Proteins from SDS-PAGE
High-HLT and low-HLT were electroeluted from SDS-PAGE 
gel slices for the purpose of performing a Western blot. 
High-HLT and low-HLT (240 fig of each) were TCA precipitated 
and electrophoresed as described above. High-HLT was 
electrophoresed on two gels, loading 20 fig per lane in 12 
total lanes. After electrophoresis, the gels were stained 
with copper stain, which stains the gel a light blue while 
leaving the protein bands unstained, and the bands 
containing high-HLT were cut out of the gels, destained, and 
loaded in an IBI, Model UEA, electroelution apparatus. The
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protein was electroeluted from the gel slices into 7.5 M 
NH^acetate at 50 V for 2% hours. The Nl^acetate solution 
containing the high-HLT was removed from the apparatus, 
separated into 6 microcentrifuge tubes and the protein was 
precipitated with TCA as described previously. The 
procedure was repeated with low-HLT. It was estimated that 
each tube contained approximately 20 pg of protein.
Active Site Titration
Active site titrations were performed on each tryptase 
isozyme using the titrant 4-methylumbelliferyl p- 
guanidinobenzoate hydrochloride (MUGB), which reacts with 
the active site serine of trypsin-like enzymes (Jameson et 
al., 1973). The excitation and emission wavelengths were 
365 nm and 445 nm, respectively, and known concentrations of 
the fluorescent product, 7-amino-4-methyl coumarin (AMC), 
were used as standards. A stock solution of 0.1 H AMC in 
0MS0 was diluted 1:100 with 0.1 M HEPES, 10 pH heparin, 10% 
glycerol, 0.05% Brij, 0.02 NaN3, pH 7.5 to produce a 1 
nmol/ml solution. The fluorimeter was calibrated to zero 
against 500 pmol of substrate in l ml of assay buffer. A 
solution containing 100 pmol/ml of AMC in assay buffer was 
used to set the fluorimeter manually to a value of 100. 
Standards of 10, 20, 40, 60, and 80 pmol in a final volume 
of 1 ml were read and the fluorescence values were plotted 
against the molar values to produce a standard line. Five
31
hundred pmol of substrate and a range of 20-200 pmol of 
enzyme was used per assay in a final volume of l ml.
Dealvcosvlation of Tryptase Isozymes
Two aliquots of 20 fig each of high-HLT and low-HLT were 
TCA precipitated in 1.5 ml microcentrifuge tubes by adding 
TCA to each sample for a final concentration of 20% and 
incubating the samples on ice for 1 hour, followed by 
centrifugation and washing of the precipitates twice with 
700 Mi of cold 10% TCA and twice with 700 Mi of cold acetone 
and drying at room temperature. The precipitated protein 
was resolubilized by adding 10 Mi of 20 mM Tris pH 7.5 
containing 0.5% SDS, 50 mM /3-ME and 0.02% NaNj and heating 
at 95°C for 5 minutes. To one tube of each isozyme, 5 Mi of 
7.5% NP-40 was added along with 1.2 Mi of N-Glycanase enzyme 
(9.1 M9/roi) and 13.8 Mi of dH20 was added to all four tubes. 
The samples were incubated at 43°c for 21 hours followed by 
the addition of 25 Mi SDS ammediol sample buffer containing 
1% 0-ME and electrophoresis as described previously using 25 
Ml of each sample, a 10% 1.5 mm gel, and colloidal Coomassie 
Brilliant blue stain.
High-HLT was also deglycosylated without denaturation 
and reduction to determine if the activity was reduced as a 
result of deglycosylation. One hundred Mi (4.8 fig) of high- 
HLT was incubated with 2 Mi of N-Glycanase at 43°C for 21 
hours. A control of 100 Mi of high-HLT with no N-Glycanase
was also incubated as above. After cooling, the control, 
the treated sample, and the high-HLT pool before incubation 
at 43°c were assayed using Cbz-Lys-SBzl as the substrate. 
Fifty /Jl of the control and the treated sample were then TCA 
precipitated, electrophoresed on a 10% 1.0 mm SDS gel and 
stained with silver stain.
Western Blot Analysis
Proteins were electroblotted onto either Immobilon-P or 
PVDF-Plus membrane. Electrophoresis of proteins to be 
transferred was carried out as above except that the gel 
thickness was reduced to 1.0 mm. The gels were subsequently 
equilibrated in 48 mM Tris, 39 mM glycine, 20% MetOH pH 9.2 
and the proteins were transferred to the membrane at 15 V 
constant voltage for 40 minutes in a Bio-Rad Transblot SD 
Semi-Dry Transfer Cell. The membranes were blocked with 3% 
fish gelatin or BSA for one hour and exposed to primary 
antibody for 15 hours with gentle shaking at room 
temperature. The primary antibody solution for analysis of 
high- HLT or low-HLT consisted of a 1:2000 (v/v) dilution of 
rabbit anti-HLT antibody in TBS (20 mM Tris 500 mM NaCl 
0.02% NaN3 pH 7.5). The secondary antibody solution 
consisted of a 1:2000 (v/v) of goat anti-rabbit IgG antibody 
conjugated with alkaline-phosphatase in TBS. The reactive 
proteins were visualized by development of the alkaline- 
phosphatase with NBT/BCIP, The primary antibody solution
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for analysis of the HMWK cleavage products consisted of a
1:1000 (v/v) dilution of a monoclonal antibody to the
carboxy terminal region of HMWK in TTBS (20mM Tris 500mM 
NaCl 0.05% Tween-20 0.02% NaN} pH 7.5) with 1% gelatin. The 
membranes were then exposed to Protein 6 Gold solution (a 
1:25 dilution of the stock solution provided in 20 mM 
citrate pH 5.5 containing 500 mM NaCl, 0.1% BSA, 0.05% 
Tween-20, 0.02% NaN3 and 0.4% fish gelatin) to detect bound 
IgG and further developed using Bio-Rad's Bilver enhancement 
procedure. This involved incubating the membrane in citrate 
buffer (0.2 M citrate, 75 mM sodium citrate pH 3.7) for five 
minutes followed by incubation for 5-15 minutes in 
enhancement solution (a mixture of 0.11 g of silver lactate 
dissolved in 10 ml of dH20 with 0.85 g of hydroguinone
dissolved in 90 ml of citrate buffer) in the dark. The
enhancement reaction was stopped by rinsing the membrane 
with dH20 and the silver was fixed on the membrane by 
rinsing with a 1:10 dilution of the fixing solution in dH20 
for five minutes.
Gel Filtration
Sephacryl S200-HR column material (155 ml) was washed 
with dH20, equilibrated with 10 mM MES, 1.5 M NaCl, 20% 
glycerol, 0.02% NaNj pH 6.1, and poured into a 1.5 x 88 cm 
glass chromatography tube. The void volume (V0) was 
determined to be 60 ml by applying 500 nl of a solution of
blue dextran (MW = 2000 kDa) with an A2I0 of 0.5 to the 
column, eluting at 0.5 ml/minute. To calibrate the column 
further, additional standards solutions were made up as 
follows: IgG (3 mg/ml, A2J0 = 2.2, MW - 150 kDa); BSA (4
mg/ml, AjS0 = 5.0, MW = 67 kDa); and chymotrypsinogen A (4 
mg/ml, Aj(0 = 15, MW <= 25 kDa). IgG (500 jil) was loaded on 
the column and eluted with a flow rate of 0.5 ml/minute. 
Fifty ml of buffer was collected into a graduated cylinder 
before collecting 70 fractions. The A210 of each fraction 
was read and plotted on the Y-axis vs. the fraction number 
on the x-axis. The chromatography and plotting described 
above was repeated using BSA as the standard and again using 
chymotrypsinogen A (except that 250 /il was loaded). Then 
new solutions of the three standards were prepared with 
concentrations of 8 mg/ml, 250 /il of each standard was mixed 
and the mixture was chromatographed as above. A solution of 
tryptase containing both high-HLT and low-HLT (A^ o = 0.226, 
approximate total protein =1.45 mg) was concentrated from 
18 ml to 1.5 ml in an Amicon pressure cell using a 10,000 
MWCO (YM-10) membrane and chromatographed on the 
standardized column. The absorbance of the fractions was 
read at 280 nm and a microtiter plate assay of the fractions 
was performed as previously described. The peaks of 
activity were pooled separately and analyzed by SDS-PAGE and 
Western blotting.
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Inhibitor Assays Using cbz-Lvs-SBzl as the substrate
The inhibitors tested for activity against high-HLT 
using Cbz-Lys-SBzl as the substrate were recombinant human 
Alzheimer's amyloid precursor protein inhibitor (APPI), 
human inter-a-trypsin inhibitor (Ial), recombinant bovine 
ArglJGlu5Iaprotinin (also known as bovine pancreatic trypsin 
inhibitor or Trasylol), recombinant human secretory 
leukocyte proteinase inhibitor (SLPI), Ascaris suum trypsin 
inhibitor (ASTI), and ecotin (a trypsin inhibitor from E. 
coli). Curcurbita maxima trypsin inhibitor-III (CMTI-III; a 
trypsin inhibitor from squash seed) was tested with high-HLT 
and low-HLT.
SLPI. Ecotin. and ASTI. Fifty nl of high-HLT (37 
ng/ml; 57.5 pmol) and 575 pmol of inhibitor (a 1:10 
enzyme:inhibitor molar ratio) was added to 100 ftl of assay 
buffer (0.1 H HEPES pH 7.5 containing 0.05% Brij 35 and 
0.02% NaN3) in a 1 ml cuvette and incubated at room 
temperature for 10 minutes, 20 minutes or 60 minutes. 
Remaining tryptase activity was assayed using the Cbz-Lys- 
SBzl substrate as previously described. Controls were exact 
duplicates of the samples except that no inhibitor was 
added.
APPI and Ial. Assays were performed in 1 ml 
spectrophotometric cuvettes at room temperature using a 
1:100 enzyme:inhibitor molar ratio. Inhibitors (APPI, 18.4
Ml = 2.88 nmol = 18.4 pg; or Ial, 170 nl - 2.88nmol = 634 
Mg) were added to 200 Ml of assay buffer (0.1 M HEPES pH 7.5 
containing 10 pK heparin, 10 % glycerol, 0.05% Brij 35, and 
0.02% NaNj) containing 25 pi of high-HLT (28.75 pmol; 0.93 
fig) and incubated at room temperature for 3 hours. A 
control of 25 pi of high-HLT in 200 pi of assay buffer was 
also incubated as above. Remaining tryptase activity was 
assayed with Cbz-Lys-SBzl substrate as previously described. 
This experiment was repeated using 400 m! of assay buffer 
and 1.44 nmol of each inhibitor and 14.38 pmol of high-HLT. 
Also included were assays using 0.1 M Tris buffer pH 8.0, 
8.5, and 8.8. The incubation and assay conditions were 
identical to the ones described above.
ArQlsGluiJ aorotinin. This procedure was performed 
essentially as above using 200 pi of assay buffer (0.1 M 
HEPES pH 7.5 containing 10 m** heparin, 10 % glycerol, 0.05% 
Brij 35, and 0.02% NaNj), 25 Ml of high-HLT (28.6 pmol; 915 
ng), and 18.7 pi of Arg15GluM aprotinin (2.88 nmol; 18.7 pg). 
A control was performed using 200 Ml of assay buffer and 25 
Ml of high-HLT. The samples were incubated at room 
temperature for 10 minutes, followed by an activity assay 
using Cbz-Lys-SBzl as described above.
CMTI-III. This procedure was performed as above using 
350 Ml the above assay buffer, 140 pmol of CMTI-III (4.6 
Ml of a 100 pg/m1 solution; 460 ng) and 3 pmol of active
low-HLT (20 pmol of protein; » a 1:50 molar E:I ratio based 
on active sites of low-HLT). A control was performed using 
350 pi of assay buffer and 1.4 pmol of low-HLT. The samples 
were incubated at room temperature for four hours, followed 
by an activity assay using Cbz-Lys-SBzl as described above. 
This experiment was repeated using 350 pi of HEPES assay 
buffer at pH 7.5, or Tris assay buffer at pH's 8.0 or 8.5 
per sample. Low-HLT (20 pmol of protein) and CMTI-III (2 
nmol)(a 1:100 molar E:I based on protein concentration or a 
1:667 E:l based on active sites of low-HLT) were added to 
each sample cuvette and incubated and assayed as above. 
Identical assays were also performed using 100 pi of pH 8.0 
assay buffer, 20 pmol of low-HLT or 5 pi of high-HLT 
(concentration not recorded), and 2 nmol of CMTI-III.
q?M and g,i, Activity Assay
Bovine alpha-2-macroglobulin (a2M) (9.8 mg/ml =13.5 
nmol/ml) that had been stored at -80°C for two years was 
diluted l:l with 0.1 M Tris pH 8.0 (assay buffer). Porcine 
trypsin (100 pi of a 2 nmol/ml solution =0.2 nmol) was used 
per reaction. A 6% solution (w/v) of azocasein in dHzo was 
used as the substrate due to the unique mechanism of action 
of ck3M (refer to Results). A series of reactions were set 
up in 1.5 ml microcentrifuge tubes as follows:
1) blank = 100 pi azocasein + 900 pi AB (assay buffer)
2) 100 pi trypsin + 800 pi AB
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(»o.67 nmol)
3) " + 790 #il AB + 10 fil OjM (*0.07 nmol)
4) » + 780 Hi AB + 20 /il
5) " + 770 Ml AB + 30 Ml
6) " + 760 Ml AB + 40 Ml
7) " + 750 Ml AB + 50 fil
8) •• + 725 Ml AB + 75 Ml
9) " + 700 Ml AB + 100 Ml
The reaction was started by the addition of 100 Ml °f 6% 
azocasein to each tube, followed by incubation at room 
temperature for 20 minutes. The reaction was stopped and 
the undigested azocasein and other proteins were 
precipitated by the addition of 200 Ml of 20% TCA to each 
tube. The samples were centrifuged for 5 minutes and the 
absorbance of each supernatant was read at 366 nm. The 
basis of this assay is that uncleaved proteins are more 
readily precipitated than small cleavage products. 
Therefore, the control (sample 2), containing only trypsin 
and azocasein, would theoretically have the largest amount 
of protein (cleaved) left in the supernatant after TCA 
precipitation and centrifugation and, consequently, would 
retain the highest absorbance at 366 nm. As increasing 
amounts of inhibitor were added, the A ^  of the samples 
should decrease due to the decreased amount of enzyme 
available to digest the azocasein. Sample 2 (no inhibitor) 
was designated as producing 100% activity based on the 
absorbance relative to the blank and the absorbances of
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samples 3 - 9  were used to determine the percent of activity 
relative to sample 2. The percent activity (Y-axis) was 
plotted against the pi of a2M (X-axis) to determine the 
relative activity of the a2M.
The above assay was repeated using rat alpha-1- 
inhibitor-3 (a,I3) (6.4 mg/ml = 33.7 nmol/ml) as the 
inhibitor. The stock solution was diluted 1:5 with assay 
buffer and the amounts used were 10, 20, 30, 40, 50, 75,
100, 150 ftl (»0.Q7 nmol - 1.0 nmol). The amount of assay 
buffer used per reaction was adjusted accordingly to produce 
a final reaction volume of l ml.
Inhibitor Assays Using HMWK as the substrate
The inhibitors tested for activity against the tryptase 
isozymes using HMWK as the substrate were bovine a2M, rat 
a,I3 (the rat equivalent to human a2M), APPI, Ial, ASTI, SLPI 
and CMTI-III.
a,M and HMWK was used as the substrate for these
inhibitory assays of tryptase and trypsin was used as a 
control enzyme. High-HLT (0.88 pmol of tetrameric enzyme, 
3.52 pmol of active sites; 2.64 pi of a 46.5 pg/ml solution) 
was added to each of three 1.5 ml microcentrifuge tubes 
containing 240 pi of assay buffer (0.1 M HEPES pH 7.5 
containing 0.05% Brij 35 and 0.02% NaNj). To one of the 
tubes, 2.6 pi (2.6 pg, 3.51 pmol) of a2M was added and to 
another tube 2.64 pi (1.34 pg, 3.51 pmol) of a,I3 was added
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(a 1:4 molar ratio of E:1 based on a tetrameric enzyme or a 
1:1 based on tryptase active sites) and all three tubes were 
incubated at room temperature for 30 minutes. Trypsin was 
added to three additional tubes containing 240 /il of assay 
buffer and the same amount of ajM and atI3 as above was added 
to two of these tubes and incubated as above. After 30 
minutes, 258 (il (50 ng, 438 pmol; a 1:125 molar ratio of E:S 
based on number of active sites of enzyme) of HMWK was added 
to each tube and 130 jil ( 25 219 pmol) of HMWK was added
to a seventh tube for a control and all the tubes were 
incubated at 37°c for 20 minutes. The reaction was stopped 
by the addition of cold 40% TCA for a final concentration of 
20%. After centrifugation, the precipitates were washed 
with cold 10% TCA and acetone and dried. The samples were 
solubilized with 50 /il of Tris-HCl sample buffer containing 
5% /J-ME and heated at 95*C for 10 minutes and cooled.
Twenty /il (20 /ig) of each sample were analyzed on a 7% SDS- 
PAGE gel using the ammediol buffer system and the proteins 
were visualized with colloidal Coomassie Brilliant Blue 
stain.
Arg15GluMaprotlnin. Trypsin (3.52 pmol) or high-HLT 
(3.52 pmol) and inhibitor (352 pmol) were added to each of 
seven 1.5 ml microcentrifuge tubes containing 400 /il of 
reaction buffer of either pH 7.5 or pH 9.1 (0.1 M HEPES pH 
7.5 containing 10 /tM heparin, 10 % glycerol, 0.05% Brij 35,
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0.02% NaN3 or 0.1 M Tris pH 9.1 containing the same 
additives) as listed below:
1) pH 7.5 + HMWK
2) n + ii +
3) i + it +
4) n + ii +
S) ti + ii .f
6) pH 9.1 + ii 4.
7) ii + " +
The E:I ratio was 1:200
+ inhibitor
(352 pmol)
incubating the enzyme and inhibitor at room temperature for 
30 minutes, HMWK (20 jug; 176 pmol) was added to each tube 
and an additional 60 minute incubation was allowed at room 
temperature. The reactions were stopped by TCA 
precipitation and the samples were prepared and 
electrophoresed on a 7%, 1.5 mm gel as previously described.
APPI. Ial. ASTI and SLPI. HMWK (20 /ig; 176 pmol) was 
put into each of six 1.5 ml microcentrifuge tubes containing 
400 fil of reaction buffer (0.1 M Tris pH 8.5 containing 10 
/iM heparin, 10 % glycerol, 0.05% Brij 35 and 0.02% NaN}) . 
High-HLT (3.52 pmol; 113 ng) was added to each of five of 
the tubes, and 352 pmol of APPI, Ial, ASTI or SLPI were 
added to four of the tubes containing the high-HLT (for a 
1:100 molar ratio of E:I). All 6 tubes were incubated at
room temperature for 30 minutes. HMWK (176 pmol) was then 
added to all tubes containing high-HLT (for a 1:50 molar 
ratio of E:S) and the samples were incubated at room 
temperature for 60 minutes. The samples were then 
precipitated with TCA as previously described and were 
analyzed by SDS-PAGE. A 7% 1.0 mm gel was used and the 
samples were visualized using colloidal Coomassie Brilliant 
blue stain.
CMTI-III. Low-HLT (2.22 pmol of protein or 0.33 pmol 
of active sites; a 1:100 E:I ratio based on protein 
concentration or a 1:667 ratio based on number of active 
sites of low-HLT) or high-HLT (2.12 Ml/ concentration not 
recorded) was incubated with CMTI-III (222 pmol) in 1.5 ml 
microcentrifuge tubes containing 315 Ml of assay buffer (0.1 
M HEPES pH 7.5 containing 10 mM heparin, 20% glycerol, 0.05% 
Brij 35, 0.02% NaNj) for 4 hours at room temperature. HMWK 
(443 pmol; 50 ng; a 1:200 E:S ratio based on protein 
concentration or a 1:1342 E:S ratio based on number of low- 
HLT active sites) was added to each tube and the mixtures 
were incubated for another 30 minutes at room temperature. 
Each sample mixture was then divided into 3 tubes containing 
146 Ml each and the proteins were precipitated by the 
addition of 1314 Ml of Ice cold absolute EtOH to each tube 
and storage at -20°c overnight. A control containing 126 Ml 
of assay buffer, 0.89 pmol of low-HLT, and 20 ng of HMWK was
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prepared in the same way and precipitated in a single tube 
using 1350 pi of cold EtOH* The precipitated proteins were 
collected by centrifugation, the supernatant was discarded, 
and the precipitates were dried at room temperature. The 
samples were solubilized with 10 pi of IX SDS ammediol 
sample buffer containing 1% 0-ME, the control with 30 pi of 
the same sample buffer and 50 pi of sample buffer were added 
to 10 pi of MW standards. All tubes were heated to 95°C for 
10 minutes and cooled. The samples and standards were 
electrophoresed on an 8% 1.5mm SDS-polyacrylamide gel as 
previously described and stained with colloidal Coomassie 
Brilliant blue.
Comparison of Inhibitory Effects of SLPI on High-HLT and
Low-HLT
In this assay, the inhibitory activity of SLPI on high- 
HLT and low-HLT cleavage of HMWK was compared. A 1:50 E:S 
molar ratio (« a 1:53 ratio for high-HLT and a 1:331 ratio 
for low-HLT based on the number of active sites) and a 1:100 
E:I molar ratio (« a 1:105 ratio and a 1:662 ratio for high- 
HLT and low-HLT, respectively, based on the number of active 
sites) was used. Five 1.5 ml microcentrifuge tubes each 
containing 400 pi of assay buffer (0.1 M HEPES pH 7.5 
containing 10 pM heparin, 10% glycerol, 0.05% Brij 35 and 
0.02% NaN3) were incubated at room temperature for 30 
minutes after the following additions:
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1) no addition
2) high-HLT (3.51 pmol or 3.33 pmol of active sites)
3) high-HLT (3.51 pmol) and SLPI (351 pmol)
4) low-HLT (3.51 pmol or 0.53 pmol of active sites)
5) low-HLT (3.51 pmol) and SLPI (351 pmol)
HMWK (175.5 pmol) was added to all 5 tubes followed by a 
second incubation for 60 minutes. The reactions were 
stopped by TCA precipitation as previously described and the 
samples were analyzed by SDS-PAGE using an 8% 1.5 mm gel.
The proteins were visualized using colloidal Coomassie 
Brilliant blue stain.
Tryptase cleavage of Laminin. Fibrinogen, and Fibronectin
Several naturally occurring proteins were tested as or 
confirmed as substrates for one or both of the tryptase 
isozymes. These included fibrinogen (Schwartz et al.,
1985), HMWK (Maier et al., 1983), and VIP (Tam and Caughey,
1990), which had been reported in the literature as tryptase 
substrates, and laminin and fibronectin, which had not been 
previously tested. Cleavage of HMWK and VIP by high-HLT and 
low-HLT is described in another section. In this 
experiment, laminin, fibrinogen, or fibronectin (20 fig) were 
tested as substrates for high-HLT. Laminin contains 3 
chains with a combined MW of approximately 1000 kDa. The 
stock solution contained 680 pg/ml (680 pmol/ml); therefore, 
20 pmol egualed 20 fig. Fibrinogen has a MW of 340 kDa. The 
stock solution contained 1 mg/ml (2.94 nmol/ml); therefore,
58.8 pmol equaled 20 /xg. Fibronectin contains 2 chains with 
a combined MW of 500 kDa. The stock solution contained 600 
Mg/ml (1.2 nmol/ml); therefore, 40 pmol equaled 20 ftg, A 
1:200 E:S molar ratio was used for each substrate. Six 1.5 
ml microcentrifuge tubes containing 200 til of assay buffer 
(0.1 M HEPES pH 7.5 containing 10 mM heparin, 10% glycerol, 
0.05% Brij 35, and 0.02% NaN3) and the following amounts of 
substrate and enzyme were incubated at room temperature for 
30 minutes:
1) 20 pmol of laminin
2) 20 pmol of laminin and 0,1 pmol of high-HLT
3) 58.8 pmol of fibrinogen
4) 58.8 pmol of fibrinogen and 0.294 pmol of high-HLT
5) 40 pmol of fibronectin
6) 40 pmol of fibronectin and 0.2 pmol of high-HLT
The reactions were stopped and the proteins precipitated 
using cold 40% TCA as described under HMWK Cleavage. Thirty 
fil of IX SDS ammediol sample buffer containing 1% 0-ME was 
added to the dried samples and 20 fil of the same sample 
buffer was added to 10 fil of MW standards followed by
heating at 95°c for 5 minutes and cooling. Twenty /*! of
each sample were loaded on a 7% 1.0 mm gel and the samples 
and standards were electrophoresed as described previously 
and visualized with colloidal Coomassie Brilliant blue. A 
second gel, a Bio-Rad prepoured 4-20% polyacrylamide gel, 
was run using the remainder of the samples and additional
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standards. A Tris-glycine running buffer was used (25 mM 
Tris, 208 mM glycine, 0.5% SDS pH 8.3) and the gel was run 
at a constant voltage of 200 V. The proteins were 
visualized using the Bio-Rad Silver Stain kit.
Carboxvmethvl-papain Column Preparation
CM-papain column material was prepared by a 
modification of a previously published method (Johnson et 
al., 1987). One hundred ml of SpectraGel A6 agarose column 
material was washed with cold 1.5 M Na2C03 and incubated with 
25 g of CNBr dissolved in 25 ml of acetonitrile at room 
temperature with stirring in a fume hood until the mixture 
appeared uniform. The column material was then washed 
thoroughly on a Buchner funnel with cold dH20 followed by 
0.1 M Na2HP04 pH 7.8 (coupling buffer). Fifty mg of papain 
(twice crystallized, Na acetate suspension) dissolved in 30 
ml of coupling buffer was incubated with the column material 
overnight at 4°C, The mixture was warmed to room 
temperature and 2 ml of ethanolamine was added (to block an 
unreacted CNBr coupling groups) and allowed to react for 30 
minutes, followed by washing the column material with one 
liter of 0.2 M Na acetate 0.5 M NaCl pH 4.5 and one liter of 
0.05 M Tris. The Ajl0 of the initial wash solution was 
checked and compared to the unreacted papain solution to 
determine the amount of papain coupled to the column 
material (23 mg). The column material was washed with 0.2 M
Tris pH 8.5 and suspended in 100 ml of the same buffer. 
Papain was activated with 0-ME at a final concentration of l 
mM, which assures a free active site thiol group, followed 
by the addition of 27.9 mg of ICH3C00H (dissolved in 1 ml of
1 M NaOH) for a final concentration of 1.5 mM and incubation 
at room temperature for 15 minutes to carboxymethylate the 
cysteine residues present in the papain. The column 
material was washed thoroughly with dH20 and then with 50 mM 
Na2HP04 0,02% NaNj pH 7.5.
Kininogen Purification
HMWK was purified from frozen human plasma by a 
previously published method (Johnson et al., 1987). 
Approximately 200 ml of plasma was thawed by immersing the 
bag in lukewarm water and the plasma was transferred to a 
plastic beaker. Inhibitors were immediately added to 
prohibit plasma proteases from degrading the kininogens.
The inhibitors added were 10 mM benzamidine HCl (inhibits 
trypsin-like serine proteinases), 40 /xg/ml polybrene (blocks 
negatively charged surfaces), 2 mM EDTA (inhibits 
metalloproteinases by chelating metal ions), 0.2 mM PMSF 
(irreversibly inhibits serine proteases by binding to the 
active site serine), and 0.2 mg/ml SBTI (inhibits serine 
proteinases). After adding N a d  to a final concentration of
2 M, the plasma was centrifuged at 16,300 x g (5°C) for 30 
minutes and the supernatant was incubated with 78 ml of
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carboxymethyl-papain Sepharose column material equilibrated 
with 50 mM Na2HP04 2 M Nacl pH 7.5 containing 1 mM 
benzamidine, 40 /jg/ml polybrene, 2 mM EDTA, 0.2 mM PMSF, 
0.02% NaNj in a plastic flask for 45 minutes at room 
temperature. The column material was collected on a Buchner 
funnel, washed with equilibration buffer and poured into a 
siliconized glass chromatography tube. The column was 
further washed with equilibration buffer until the Ajio fell 
below 0.01 followed by washing with 100 ml of 50 mM Na2HP04 
pH 7.5 containing 2 mM EDTA, 0.1 mM PMSF, 0.02% NaNj. The 
kininogens were eluted from the column with 50 mM Na2HP04 pH 
11.5 containing 2 mM EDTA and 0.02% NaNj and 3 ml fractions 
were collected at 2 minute intervals into plastic tubes 
containing 125 fil of l M Na acetate pH 4.4 containing 4 mM 
PMSF to achieve a final concentration of 0.2 mM PMSF and a 
pH of 5.5. The absorbance of the fractions was read at 280 
nm and the appropriate fractions were pooled (50 ml) and 
concentrated in an Amicon pressure cell using a 30,000 MW 
cutoff membrane (YM-30) to 20 ml and the sample was diluted 
to 50 ml with 10 mM Na acetate pH 5.5 containing 1 mM 
benzamidine and 0.2 mM PMSF and the sample was concentrated 
to 6 ml. Three ml of the sample were loaded on a Mono Q 5/5 
HPLC column equilibrated in 10 mM Na acetate pH 5.5 at 0,5 
ml/minute and the column was washed with equilibration 
buffer at 1.0 ml/minute until the Ajm reached zero. LMWK 
was eluted with a NaCl gradient of 0-0.25 M over 30 minutes
followed by HMWK elution with a 0.25-0.5 M NaCl gradient 
over 5 minutes. The remaining 3 ml of the concentrated 
sample from the carboxymethyl-papain Sepharose column was 
chromatographed on the Mono Q column in the same way. The 
fractions corresponding to the peak were pooled and 
analyzed by SDS-PAGE with reduction. The HMWK pool produced 
a major band with an M, of 114 kDa as expected for intact 
HMWK and a contaminating band of M, 55 kDa and LMWK appeared 
as a 67 kDa band. The contaminant co-purified with HMWK, 
even in the presence of 5 M urea, and most likely was the 
amino terminal region of HMWK resulting from autolysis by 
kallikrein during preparation and storage of the blood 
plasma (Kato et al., 1981). This band did not react with 
antibodies specific for the carboxy terminal portion of 
HMWK.
HMWK Cleavage
All cleavage reactions were performed in 1.5 ml 
microcentrifuge tubes at room temperature. To 1000 fil of 
reaction buffer (0.1 M HEPES 10 jiM heparin 10% glycerol 
0.05% Brij 0.02% NaN3 pH 7.5), 1.74 nmol (443 pg/ml) of HMWK 
and the appropriate amount of enzyme was added. A 1:50 
molar ratio (enzyme:substrate) was used for high-HLT while a 
1:1300 molar ratio was used for low-HLT, based on the number 
of active sites of tryptase. These enzyme-substrate ratios, 
which were based on preliminary experiments, yielded similar
cleavage rates. Aliquots of twenty pg of HMWK were 
withdrawn at each of five time points, 5, 10, 20, 40, and 60 
minutes, and the reaction was immediately terminated by 
precipitating the proteins with either TCA or ethanol. TCA 
precipitation, used for the samples on the gels shown in 
Figure 2, involved adding TCA to each sample for a final 
concentration of 20% and incubating the samples on ice for 1 
hour, followed by centrifugation and washing of the 
precipitates twice with 700 pi of cold 10% TCA and twice 
with 700 pi of cold acetone and drying at room temperature. 
The TCA precipitation protocol used initially did not 
recover some smaller fragments that were subsequently 
detected when ethanol precipitation was used. Ethanol 
precipitation, used for the samples on the Western blot 
shown in Figure 3, involved adding nine volumes of ice cold 
absolute ethanol to each sample followed by incubation for 
12 hours at -20°C. Precipitates were collected by 
centrifugation at 14,000 rpm (4°C) for 5 minutes and were 
dried at room temperature.
Sequencing of HMWK Fragment
HMWK (40 pg; 350pmol) was incubated with either 7 pmol 
of high-HLT (E:S of 1:50) or 1.76 pmol of low-HLT (E:S of 
1:200 based on protein concentration or 1:1326 based on 
number of active sites) in assay buffer for 10 minutes at 
room temperature (cleavage corresponds to the 10 minute time 
period in Figure 2) followed by precipitation with cold
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trichloroacetic acid as described under HMWK Cleavage.
Eight pg of the sample were loaded in each of five lanes of 
a 6% SDS-PAGE gel and then electrophoresed and 
electroblotted onto Immobilon-P as described under 
Electrophoresis and Western Blot Analysis. The membranes 
were lightly stained with 0.1% Coomassie R-250 in 50% MetOH 
10% acetic acid (v/v), dried, and sent to Dr. Mark Lively at 
Bowman Gray School of Medicine (Winston-Salem, NC) for amino 
acid sequencing.
VIP Cleavage
Cleavage of VIP by the tryptase isozymes was performed 
in 1.5 ml microcentrifuge tubes at room temperature. Thirty 
nmoles of VIP were added to 500 pi of reaction buffer and 
24.7 pmoles of either high-HLT or low-HLT active sites (E:S 
of 1:17000). Equal aliquots were withdrawn from the 
reaction mixture at 5, 10, 20, 30, and 60 minutes and 5 pi 
of acetic acid was added to each aliquot to stop the 
reaction, followed by the addition of 130 pi of 0.1% TFA 
(HPLC buffer A). The samples were then filtered and applied 
to a Cu column at 0.5 ml/minute. The column was eluted at 
0.5 ml/minute with a 10-40% gradient of buffer B (0.1% TFA 
in acetonitrile) over 20 minute and the absorbance was 
monitored at 210 nm.
Amino Acid Analysis of VIP Cleavacfe Products
The peak at 24.34 minutes from the high-HLT cleavage of
VIP and the peak at 28.54 minutes from the low-HLT cleavage 
of VIP were collected in separate microcentrifuge tubes.
The samples were transferred to HH03-cleaned 6 x 50 nun glass 
tubes and dried in a SpeedVac for 45 minutes, then 
hydrolyzed in an evacuated vial with 6 N HC1 at 110°c for 23 
hours. Hydrolyzed samples and amino acid standards (500 
pmol) were dried as before and PITC derivatized according to 
the Pharmacia protocol. This involved the addition of 10 fil 
of MetOH:TEA:H20 (2:2:1) to each tube and drying followed by 
addition of 20 fil of MetOH:H20:TEA:PITC (7:1:1:1) to each 
tube and drying. Immediately before use, samples or 
standards were solubilized in 25 fil of HPLC buffer A (940 ml 
of 140 mM sodium acetate trihydrate containing 0.05% v/v 
triethylamine mixed with 60 ml of acetonitrile) and 
chromatographed on a Haters Pico-Tag column at 1 ml/minute 
with a 0-46% buffer B (60% acetonitrile in H20) convex 
gradient (curve #5) over 15 minutes. Quantification of the 
amino acids was accomplished with Waters Maxima software on 
an IBM/AT computer.
CHAPTER 3 
RESULTS
Purification and Separation of the Two Tryptase Isozymes 
Purification of tryptase from human lung tissue 
produced two pools of activity with M, values of 
approximately 29 kDa and 33 kDa (Figure 3). The 29 kDa pool 
(low-HLT) was obtained in small quantities (15% of high-HLT) 
and was more difficult to purify. A variety of columns and 
loading/elution conditions were tried with the goal of 
improving isozyme separation, purity and yield over previous 
purification protocols, with little success. A Dowex-lX 
column was used to reduce the viscosity of the crude 
extract. Dowex binds heparin and other negatively charged 
molecules while allowing tryptase to be collected in the 
flowthrough. The recovery of activity was 56% and the 
viscosity was only slightly reduced. This pool was dialyzed 
and chromatographed on a heparin-Sepharose column and eluted 
with increasing salt. The binding capacity of the heparin- 
Sepharose was low and about 50% of the activity was detected 
in the flowthrough. Two peaks of activity eluted from the 
column but both contained numerous proteins (Figure 1 in the 
Appendix). An affinity column, p-aminobenzamidine agarose, 
was also tried but also exhibited low binding capacity. The 
CPC extract was loaded on at pH 7.5, the pH at which 
tryptase is most active but less stable than at
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Figure 3. SDS-PAGE of High-HLT and Low-HLT Isozymes. Lane 
A, high-HLT (10 #ig); Lane B, low-HLT (10 /xg). Samples and 
standards were denatured and reduced before electrophoresis 
on a 10% gel. Molecular weight markers were, as indicated, 
phosphorylase B (100 kDa), transferrin (78 kDa), BSA (68 
kDa), igG (50 kDa), carbonic anhydrase (29 kDa), soybean 
trypsin inhibitor (21 kDa), cytochrome c (12.75 kDa), and 
Trasylol (6.5 kDa).
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pH 6.1, and eluted with pH 4.5 buffer or 1 M NaCl buffer.
The yields of protein as detected by A3|0 were very low as 
were the yields of activity (s 10%). The sulfopropyl-type 
cation exchange columns Spectra Gel SP and Mono s HPLC were 
tried because the cation exchanger cellulose-phosphate bound 
tryptase very well. However, the binding capacities of 
these columns were lower than cellulose-phosphate and the 
NaCI in the sample had to be reduced to 0.2 M or less for 
binding to occur. Eventually, the best purification scheme 
found utilized CPC treatment of crude extracts followed by 
chromatography on butyl hydrophobic interaction 
chromatography (HIC) and cellulose-phosphate columns.
Both tryptase isozymes, along with many other proteins, 
bound to the butyl HIC column in 2 M (NH4)2S04 and eluted 
together with a decreasing (NH^St^ gradient. Elimination 
of the (NH4)2S04 and reduction of the NaCl concentration of 
the butyl pool by dialysis against MES buffer containing 0.3 
M NaCI allowed subsequent binding of both isozymes to 
cellulose-phosphate column material. High-HLT eluted from 
the cellulose-phosphate column with 10 pH heparin whereas 
low-HLT did not elute with heparin but required 1 M NaCl for 
elution. Alternately, a gradient of 0-50 /jM heparin and 0.3 
M-l.5 M NaCl dissociated both isozymes from the cellulose- 
phosphate column, with high-HLT eluting first. SDS-PAGE 
analysis showed that some low-HLT preparations contained 
minor contaminants, that coeluted from the cellulose-
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phosphate column, which required re-chromatography to 
remove. The presence of tryptase throughout the 
purification procedure was monitored by a chromogenic 
activity assay using the synthetic trypsin substrate Cbz- 
Lys-SBzl. The overall recovery of activity was usually 
about 25% with the high M, fraction representing 
approximately 85% of the total activity and the low M, form 
accounting for 15% of the activity on Cbz-Lys-SBzl. A 
representative purification table is shown in Table 2, and 
Figure 4 shows the stages of purification on SDS-PAGE.
Active site titration of the two tryptase isozymes with MUGB 
showed that the high-HLT was 95% active, whereas the low-HLT 
was only 15% active.
Structural Analyses of the Two Isozymes
Pealvcosvlation of Hlch-HLT and Low-HLT
Deglycosylation of the two isozymes was attempted in 
order to get an indication of the carbohydrate content in 
relation to the H, and to determine if the primary 
difference in size between the isozymes was due to 
glycosylation. Treating both forms of tryptase that had 
been TCA precipitated, dissolved in SDS buffer and reduced 
with DTT, with N-Glycanase (a recombinant form of 
endoglycosidase-F), yielded much sharper bands on SDS-PAGE, 
but only high-HLT decreased noticeably in M, (an approximate 
decrease of 1-2 kDa). Low-HLT remained at the same relative
Table 2. Purification of High-HLT and Low-HLT from 500 g of Human Lung Tissue. A
representative purification table for the purification of high-HLT and low-HLT shows an 
ultimate combined recovery of activity of 25%, with high-HLT representing 84% of the total 
activity. The Activity is expressed as the increase in absorbance at 410 nm/minute/ml. The 
Specific Activity is defined as the Activity/A^. The Fold Purification is based on the 
increase in Specific Activity and the Percent Recovery is based on the Total Activity in each 
pool (volume x activity) compared to the crude extract.
Total Total Specific Fold Percent
Volume fmll -^no- Activity Activity Purification Recovery
Crude lung extract 460 5750 15272 2.7 1.0 100
CPC/{NH4>3S04 extract 975 3023 19403 6.4 2.4 127
Butyl pool 110 275 13090 47.6 18 86
Cellulose-phosphate
Heparin fraction 22 7.0 3212 456 169 21
NaCI fraction 12.5 1.5 375 250 93 4
U1-o
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Figure 4. SDS-PAGE (10%) of the Progressive steps of 
Purification of High-HLT and Low-HLT. Lane A, crude lung 
extract (20 /il); Lane B, activity pool from butyl column 
before dialysis (10 fig), Lane C, activity pool from butyl 
column after dialysis (10 fig); Lane D, activity pool from 
the heparin elution of the cellulose-phosphate column (10 
fig); and Lane E, activity pool from the NaCI elution of the 
cellulose-phosphate column (10 /ig). The samples and HW 
standards were denatured and reduced before electrophoresis. 
The gel was stained with colloidal Coomassie blue.
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MW but the profile of the band changed significantly (Figure 
5A)* High-HLT was also treated with N-Glycanase without 
first TCA precipitating the enzyme and without denaturation 
and reduction with SDS and 0-ME, respectively, in order to 
test the effect of deglycosylation on the activity of high- 
HLT. SDS-PAGE analysis of this sample (Figure 5B) shows 
only a slight reduction in M,. The results of an activity 
assay of 5 ^1 of the sample and the controls are presented 
below:
Sample AA1tA/mlnute % Activity
Before treatment 0,2277 100
control 0.1574 69
Treated sample 0.1752 77
Both the control and the N-Glycanase-treated sample lost 25- 
30% of the activity in the original sample, presumably due 
to the incubation at 43°c for 21 hours. However, there is 
no significant difference in activity level between the 
control and the N-Glycanase-treated high-HLT.
Gel Filtration. Another structural study carried out 
was gel filtration to determine any differences in 
quaternary structure between the two tryptase isozymes.
After calibrating a Sephacryl S-200HR column with Blue 
dextran (MW » 2000 kDa; to determine the V„), IgG (MW = 150 
kDa), BSA (MW = 67 kDa), and chymotrypsinogen A (MW = 25
60
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Figure 5 (A). 8D8-PAGE (10%) of High-HLT end Low-HLT 
Deglycosylated Following Denaturation and Reduction. Lane 
A, high-HLT; Lane B, high-HLT treated (deglycosylated) with 
N-Glycanase; Lane C, low-HLT; and Lane D, low-HLT treated 
with N-Glycanase. Samples were denatured with SDS and 
reduced with B-ME before N-Glycanase treatment. Each sample 
lane contained approximately 10 jug of protein. Colloidal 
Coomassie blue stain was used. The samples and MW 
standards in A and B were reduced before electrophoresis.
61
kOa Std A B Std
78- 
50-
29-
21-
12.75- 
6.5-
Figura 5 (B). SDS-PAGE (10%) of High-ELT Daglycosylatad 
Without Prior Denaturation and Reduction. Lane A, high-HLT 
(2.5 fig); Lane B, high-HLT (2.5 ftg) treated with N- 
Glycanase. The sample was not denatured or reduced before 
deglycosylation. The proteins were visualized using silver 
stain.
kDa), a mixture of high-HLT and low-HLT was chromatographed 
on the column. The AII0 of the fractions were read and the 
values were plotted vs. the fraction number, yielding, as 
shown in Figure 6A, three distinct absorbance peaks with M, 
of approximately 125 kDa, 55 kDa and 28 kDa. An overlay of 
the Agio of the fractions and the corresponding activities on 
Cbz-Lys-SBzl showed that the peaks of activity corresponded 
exactly with the A2W peaks (Figure 6B). SDS-PAGE analysis 
of the three peaks of activity showed that the first and 
second peaks contained high-HLT and the third peak contained 
low-HLT (Figure 7). These data indicated that high-HLT may 
exist primarily as a tetramer, with a H, of about 125 kDa, 
while low-HLT may exist as a monomer, with a H, of about 28 
kDa. There may also be a dimeric form (M, of 55 kDa) 
containing two heterologous subunits. Western blot analysis 
of these pools was somewhat inconclusive. The two high M, 
pools migrated out of the gel onto PVDF or nitrocellulose 
membrane and reacted with the polyclonal anti-HLT antibody 
(Figure 8). The low M, pool, however, did not migrate out 
of the gel under various transfer conditions and therefore 
was not immunologically analyzed.
Inhibition Studies of Hioh-HLT and Low-HLT Using Several
Trvosin Inhibitors 
Two types of inhibitor assays were done, one using the 
small synthetic substrate Cbz-Lys-SBzl and one using the
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Figure 6 (A). Chromatogram of a Mixture of High~HLT and Low- 
HLT on a Sephacryl 8200-HR Gel Filtration Column with HW 
standards. A standard solution of 2 mg each of igG (MW =
150 kDa), BSA (MW = 67 kDa) and chymotrypsinogen A (MW = 2 5  
kDa) was chromatographed on a 1.5 x 88 cm gel filtration 
column at 0.5 ml/min. and the A],0 of each fraction was read 
and graphed. The graph was overlaid on a chromatogram of 
the A^o of fractions collected after a mixture of high- and 
low-HLT (1-1.5 mg of total protein) was applied to the 
column. The V0 had previously been determined to be 60 ml 
by chromatography of 500 fxl of a saturated solution of blue 
dextran (MW = 2000 kDa).
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Figure 6 (B). Chromatogram of a Mixture of High-HLT and 
Low-HLT on a Sephacryl S200-HR Gel Filtration Column with 
Activity Overlay. The activities of the high- and low-HLT 
fractions were measured by microtiter plate assay using Cbz- 
Lys-SBzl as the substrate and the A4t0/minute was graphed 
over the A^q of the fractions.
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Figure 7* SDS-PAGE (10%) of Peaks Collected from 
Chromatography of High-HLT and Low-HLT Mixture on Gel 
Filtration Column. Lane A, Pooled fractions 62-74 (10 fig); 
Lane B, pooled fractions 78-84 (10 fig); Lane c, pooled 
fractions 89-91 (10 fig). The samples and KW standards were 
reduced before electrophoresis and were visualized with 
colloidal Coomassie blue.
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Figure 8. Western Blot end coomaaaie stained Membrane Gal 
Filtration Peaks. Lane A, Pooled fractions 62-74 (0.5 fig); 
Lane B, pooled fractions 78-84 (5 jig); Lane C, pooled 
fractions 80-91 (5 fig). The proteins were electrophoresed 
on a 10% SDS-PAGE gel with reduction, transferred to a PVDF 
membrane, blocked with BSA, incubated with 1:2000 rabbit 
anti-HLT antibody, washed and incubated with 1:2000 goat 
anti-rabbit IgG antibody conjugated with alkaline 
phosphatase, and developed with NBT/BCIP. Lanes D, E, and P 
were duplicates of lanes A, B, and c, respectively. The 
samples were electrophoresed as above and the protein was 
transferred to PVDF membrane and visualized by staining with 
0,1% cooraassie R-250 in 25% MetOH/10% oAc (v/v).
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large protein substrate HMWK. The inhibitors tested 
using Cbz-Lys-SBzl as the tryptase substrate were SLPI, 
ecotin, ASTI, APPI, Ial, CMTI-III, and Argl5Glui2aprotinin.
The assays with SLPI, ecotin and ASTI were done using a 1:10 
E:I ratio based on protein concentration; the assays with 
APPI, Ial and ArglsGluJIaprotinin were done using a 1:100 E:I 
ratio based on protein concentration; and the assays with 
CMTI-III were done using a 1:50 E:I based on the number of 
active sites of enzyme. The results of the individual 
assays with the corresponding controls, summarized in Table 
3, show that none of the inhibitors demonstrated significant 
inhibition of tryptase.
The second type of assay, using HMWK as the substrate, 
produced results showing that one inhibitor, bovine a2M, may 
inhibit high-HLT (it was not tried with low-HLT), and one 
other inhibitor, SLPI, showed definite inhibition of both 
isozymes. The other inhibitors tested included rat 0,13, 
Arg15Glunaprotinin, APPI, Ial, ASTI, and CMTI-III. Assays 
with a3M and a,l3 used E:I molar ratios of one, based on the 
number of active sites of tryptase; assays with 
Arg13GluHaprotinin, APPI, Ial, ASTI SLPI, and CMTI-III were 
performed at an E:I ratio of 1:100, based on protein 
concentration.
Previous studies had indicated that human tryptase was 
not inhibited by human a2M nor did tryptase cleave the bait
Table 3. Inhibition Assays of High-HLT Using Various Trypsin Inhibitors. All assays were
\ *
performed at room temperature using Cbz-Lys-SBzl as the substrate. Each set of assays was 
set up separately as described in Materials and Methods. An E:I ratio of 1:100 was used for 
the trypsin controls and incubated for 20 minutes before addition of the substrate.
Control - Test of Inhibitor Activity on Trvnsin
a /minute % Activity
Porcine Trypsin Control 0.4088 100
" + APPI 0.0068 1.7
” + Ial 0.0446 ' 11
" + ArgIJGlu52aprotinin 0.0030 <1
" + ASTI 0.0267 6.5
" + SLPI 0.2226 54*
Tryptase Control
SLPI
ASTI
Ecotin
10 minutes** 
AAm /min. % Act. 
0.4820 100
0.4092 85
0.4457 92
0.4165 86
60 minutes 
AAir/min. % Act, 
0.3655 100
0.2962 81
0.3443 94
0.3246 89
C7\
03
Table 3. (cont.)
PH 7.5* 
AA^n/minute % Activity 
Tryptase Control 0.4451 100
APPI 0.4271 96
Ial 0.453 8 102
Tryptase Control
SLPI
ASTI
Ial
APPI
Arg^Glu^aprotinin
pH 3.0++ 
AA.tft/minute % Activity
0.4338
0.4309
0.4462
0.4506
0.4221
0.4230
100
99
103
104
97
98
AA|in/minute
0.4256
0.4148
0.4267
0.4662
0.4288
0.4381
PH 8.5+*
% Activity 
100 
97 
100 
109 
101 
103
’Porcine trypsin is not as well inhibited by SLPI as bovine trypsin (Smith and Johnson, 1985). 
"Times refer to the length of incubation of enzyme (E) and inhibitor (I) before addition of 
substrate. An E:I ratio of 1:10 was used for these assays.
+E:I ratios of 1:100; 3 hour incubation of E and I before addition of substrate.
++E:I ratios of 1:100; 20 minute incubation of E and I before addition of substrate.
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region (D. A. Johnson and T. J. Smith, unpublished data). A 
limited experiment using bovine o2M and high-HLT was 
inconclusive (see Figure 2 in the Appendix). The cleavage 
of HMWK was used as the control in this experiment, but was 
not carried out to completion; therefore, analysis of the 
inhibition of cleavage in the sample lanes was difficult. 
However, there was a discernable difference between the 
control and the sample containing the inhibitor, ajti, 
suggesting some degree of inhibition of high-HLT by cr2M. 
Additional experiments using high-HLT and low-HLT 
(independently) are needed to determine more definitively 
the extent of inhibition, if any, of the two tryptase 
isozymes by or2M.
Inhibition of human mast cell tryptase by SLPI had been 
previously suggested (Fritz, 1988), but no supportive data 
was provided. Therefore, SLPI was tested as an inhibitor of 
both human tryptase isozymes. SLPI inhibition of high-HLT 
and low-HLT using HMWK as the substrate is shown in Figure 
9. The cleavage of HMWK was allowed to proceed for 60 
minutes (presumably to completion) and, although over 6 
times the number of active sites of high-HLT as low-HLT were 
used, only the low-HLT control cleaved all of the substrate. 
Subsequently, it was found that low-HLT was 25 times more 
active on HMWK than high-HLT. Low-HLT also appeared to be 
more thoroughly inhibited by SLPI than high-HLT; however, a 
six-fold higher E:I ratio was used for low-HLT, based on the
71
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Figure 9. SDS-PAGE (a%) of the Inhibitory Effects of SLPI 
on High-HLT and Low-HLT. Lane A, HMWK (20 fig, 175.5 pmol); 
Lane B, HMWK and high-HLT (3,51 pmol); Lane c, HMWK, high- 
HLT and SLPI (351 pmol); Lane D, HMWK and low-HLT; Lane E, 
HMWK, low-HLT and SLPI. The cleavages represented in lanes 
B and D were allowed to proceed for 60 minutes at RT before 
being TCA precipitated for analysis. The inhibitory effects 
shown in lanes C and E were the result of incubation of the 
enzyme (HLT) and inhibitor (SLPI) at RT for 30 minutes 
followed by addition of substrate (HMWK) for 60 minutes 
before TCA precipitation. The samples and MW standards were 
reduced before electrophoresis and were visualized with 
colloidal Coomassie blue.
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number of active sites, because the experiment was performed 
with equal amounts of enzyme protein prior to active site 
titration. Therefore, although a comparison of inhibitory 
activity of SLPI on high-HLT and low-HLT was not performed, 
it was clear that both isozymes were inhibited by SLPI.
Argl5Glu5:aprotinin had been reported to inhibit tryptase 
in the degranulation supernatants of human tonsilar mast 
cells (Dietze et al., 1990); therefore, we tested this 
modified trypsin inhibitor as an inhibitor of purified 
tryptase. As shown in Figure 10, no inhibition of high-HLT 
by ArglJGlui2aprotinin was seen at pH 7.5 or 9.1, while the 
activity of trypsin on HMWK was completely inhibited by 
Arg13GluMaprotinin at pH 7,5.
Testing of Several Biological. Molecules as Tryptase
Substrates
Investigation of Laminin. Fibrinogen, and Fibronegtln_as 
Tryptase Substrates. Laminin, fibrinogen, and fibronectin 
are all fibrous proteins or precursors of fibrous proteins. 
Fibrinogen is involved in the later stages of the blood 
coagulation cascade and is converted to fibrin, which 
aggregates to form a thrombus, upon cleavage by thrombin. 
Both fibrinogen and fibronectin are involved in the 
enhancement of blood clotting, whereas both fibronectin and 
laminin are classified as adhesive proteins involved in cell 
adhesion to the extracellular matrix (Hynes, 1985). Also,
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Figure 10. SDS-PAGE (7%) of the Inhibitory Effects of 
Arg,JGlunaprotinin on High-HLT and Trypsin at pH 7.5 and 9.1.
Lane A, HMWK (20 fig, 176 pmol); Lane B, HMWK and trypsin 
(0.88 pmol) at pH 7.5; Lane C, HMWK, trypsin and 
Arg,5GluMaprotinin (88 pmol) at pH 7.5; Lane D, HMWK and 
high-HLT (1.76 pmol) at pH 7.5; Lane E, HMWK, high-HLT and 
Arg,5Gluwaprotinin (176 pmol) at pH 7.5; Lane F, HMWK and 
high-HLT at pH 9.1; Lane G, HMWK, high-HLT and 
Argl5Glunaprotinin at pH 9.1. Inhibitor and enzyme in lanes 
C, E and G were incubated at RT for 20 minutes before 
addition of substrate and a second incubation at RT for 30 
minutes followed by TCA precipitation. Samples and MW 
standards were reduced before electrophoresis were 
visualized with colloidal Coomassie blue.
both laminin and fibronectin contain relatively high numbers 
of Lys and Arg residues (Timpl et al., 1979), making them 
good possible candidates as tryptase substrates. Tryptase 
in the presence of heparin had been reported to cleave both 
the a and £ chains of fibrinogen (Schwartz et al., 1985) and 
fibronectin had been shown to be cleaved by tryptase in the 
presence of heparin (Smith, 1985). Therefore, laminin, 
fibronectin, and fibrinogen were all exposed to high-HLT and 
analyzed by SDS-PAGE with reduction. The results of these 
experiments were not definitive due to the poor quality of 
the electrophoresis gels, which are only presented in the 
Appendix. The data (Figure 3A in the Appendix) indicate 
that fibrinogen was cleaved by high-HLT, as evidenced by the 
appearance of a new band at approximately H, 65 KDa in the 
tryptase-treated sample. This agrees with the initial 
results obtained by Schwartz et al. (1985), which showed the 
production of a band of M, 65 kDa after a brief exposure of 
fibrinogen to tryptase, and the disappearance of that band 
and concurrent appearance of smaller bands following 
prolonged exposure. While no cleavage of either laminin or 
fibronectin was apparent in Figure 3A, a difference in 
banding pattern between the tryptase-treated and untreated 
fibronectin samples was detectable in Figure 3B. This 
gradient gel ran and stained poorly, but still clearly 
showed an additional band of about M, 45 kDa in lane 7 when 
compared to lane 6. Again, no cleavage of laminin was
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detectable. Additional analysis of the effect of high-HLT 
on laminin and fibronectin is needed to confirm the above 
results, and investigation of the effects of low-HLT on all 
three proteins is also necessary.
Cleavage of HMWK with High-HLT and Low-HLT
HMWK is a plasma protein which consists of a heavy 
chain, composed primarily of three cysteine proteinase 
inhibitor domains, and a light chain, containing a 
histidine-rich region that includes the procoagulant 
activity, separated by bradykinin (refer to Figure 13). 
Although the three-dimensional structure of HMWK is unknown, 
it seems likely that the highly charged light chain assumes 
a conformational structure that makes it readily available 
for interaction with other molecules, as it has been shown 
that this part of the molecule is responsible for binding to 
anionic surfaces (DeLa Cadena and Colman, 1992). Cleavage 
of HMWK by high-HLT or low-HLT produced different 
fragmentation patterns on SDS-PAGE (Figure 11). Several 
smaller fragments generated by low-HLT failed to precipitate 
with 20% TCA, but were subsequently detected by using 
concentrated samples and performing SDS-PAGE without 
precipitating the samples (Figure 4 in the Appendix). Some 
of these smaller fragments were also detected using ethanol 
instead of TCA to precipitate the samples (data not shown). 
This observation is consistent with the small fragments 
being from the carboxy terminal region that is rich in basic
amino acid residues, and therefore may be less likely to 
precipitate in an acidic environment. High-HLT cleavage of 
HMWK resulted initially in two major bands of M, 65 kDa and 
46 kDa, with the 46 kDa fragment disappearing by 40 minutes 
(Figure 11A). In contrast, low-HLT cleavage of HMWK produced 
a minor band of M, 100 kDa and two major bands of M, 75 kDa 
and 65 kDa. By 40 minutes, only the 65 kDa fragment was 
visible in Figure 11B. Western blot analysis of these 
products was performed after ethanol precipitation using a 
monoclonal antibody to the light chain of HMWK to determine 
which were the carboxy terminal fragments for sequencing.
As shown in Figure 12, a single 46 kDa fragment produced by 
the action of high-HLT on HMWK reacted strongly with the 
antibody, whereas low-HLT produced multiple fragments that 
reacted only weakly with the c-terminal antibody, including 
many fragments of less than 50 kDa, indicating numerous 
nonspecific cleavages in the HMWK light chain by low-HLT.
Limited sequencing of several cleavage fragments was 
performed by Mark Lively at Bowman Gray School of Medicine 
in Winston-Salem, NC, using an Applied Biosystems gas phase 
sequencer. In order to obtain a better understanding of the 
equipment and procedures used in automated sequencing and 
analysis, I went to Bowman Gray and observed the sequencing 
of these fragments. The results of sequencing the 46 kDa 
fragment from the high-HLT reaction indicated an amino 
terminal sequence of Asp-Gln-Gly-Xaa-Gly-Xaa-Gln,
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Figure 11* Time Course SDS-PAGE of HMWK and Products after 
Cleavage vith High-HLT and Low-HLT. Lanes are labeled with 
the length of cleavage reaction in minutes, which was 
stopped by TCA precipitation. Samples of 5 fig were loaded 
in each well of the 6% SDS-PAGE gel with reduction and the 
bands were visualized with Coomassie Blue staining. A, HMWK 
(5 /igf 219 pmol) cleaved with high-HLT (4.4 pmol; 1:50 E:S 
based on protein concentration) ; B, HMWK cleaved with low- 
HLT (1.1 pmol; 1:200 E:S based on protein concentration) . 
Molecular weight markers are the same as in Figure 3.
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Figure 12. Western Blot of HMWK and Cleavage Products with 
High-HLT and Low-HLT. Lane A, HMWK and cleavage products 
(20 fig, 174 pmol) after a 20 minute cleavage with high-HLT 
(3.48 pmol; 1:50 E:S based on protein concentration); Lane 
B, HMWK and cleavage products (20 ng, 174 pmol) after a 20 
minute cleavage with low-HLT (0.87 pmol; 1:200 E:S based on 
protein concentration). Reactions were stopped and products 
were collected by ethanol precipitation. The samples and MW 
standards were reduced, electrophoresed on an 8% SDS-PAGE 
gel and transferred to a PVDF blotting membrane. A 
monoclonal antibody to the light chain (C-terminus) of HMWK 
was used as the primary antibody. Antibody binding was 
visualized using Protein G Gold and silver enhancement.
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corresponding to HMWK residues Asp4JJ-Gln-Gly-His-Gly-His- 
Gln43t in the light chain of HMWK (Figure 13). Thus, high- 
HLT cleaves HMWK between Arg431 and Asp4]1 (or Arg«9 and Asp4JQ 
of prekininogen; Takagaki et al., 1985). Attempts to 
sequence the 75 kDa and 65 kDa bands produced by the low-HLT 
reaction were unsuccessful. Presumably they contain the 
amino terminus of HMWK, which is unavailable to Edman 
degradation due to the presence of an amino terminal 5- 
oxoproline (Kellermann et al., 1986). Due to the multiple 
c-terminal fragments produced by low-HLT, determination of a 
primary cleavage site was not possible.
cleavage of VIP bv High-HLT and Low-HLT
VIP cleavage by each of the two tryptase isozymes 
produced different chromatographic profiles when analyzed by 
C]t reverse-phase HPLC. As shown in Figure 14, the heights 
of the residual VIP peaks were approximately the same at 10 
minutes with low-HLT (Figure 14C) and at 20 minutes with 
high-HLT (Figure 14B). The enzyme/substrate ratios (based 
on the number of tryptase active sites) were the same in 
these experiments, indicating that low-HLT cleaved VIP at 
twice the rate of high-HLT. The initial major cleavage 
product resulting from cleavage by high-HLT eluted at 24.4 
minutes and the initial major cleavage product resulting 
from cleavage by low-HLT eluted at 28.4 minutes, relative to 
native VIP at 29.1 minutes (Figure 14A). Although both
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HEAVY CHAIN LIGHT CHAIN
BRADYKININ
CYSTEINE PROTEINASE INHIBITOR  
DOMAINS
1 2 3
FROCOAGVLANT
REGION
CO,
H is-L ys-H is-G lu-A rg-A sp-G ln-G ly-H is-G l
431 A  43<
HIGH-HLT
CLEAVAGE
SITE
Figure 13. Schematic Representation of HMWK showing the 
Primary Cleavage site by High-HLT. Forty fig (350 pmol) of 
HMWK was cleaved with 7 pmol of high-HLT (E:S of 1:50) for 
10 minutes and 8 fig of the sample were electrophoresed in 
each of five lanes of a 6% SDS-PAGE gel and transferred to 
an Immobilon-P membrane. Limited sequence analysis of the 
46 kDa fragment from this cleavage was performed using 
automated Edman degradation. The resulting amino terminal 
sequence of Asp-Gln-Gly-Xaa-Gly-Xaa-Gln corresponded to a 
primary site of cleavage by high-HLT at Arg<n in the 
procoagulant region of the light chain of HMWK.
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Figure 14. Reverse-phase HPLC chromatograms of VIP and the 
cleavage products generated by the activity of high-HLT and 
low-HLT. A, native VIP (20 ftg or 6 nmol); B, VIP (20 ng) 
after exposure to 0.346 pmol of active high-HLT (1:17340 
E:S) for 20 minutes; C, VIP (20 /xg) after exposure to 0.346 
pmol of active low-HLT for 10 minutes; D, VIP (20 jig) after 
exposure to 0.346 pmol of active high-HLT (1:17340 E:S) for 
60 minutes; and E, VIP (20 jig) after exposure to 0.346 pmol 
of active low-HLT for 60 minutes. Five /il of glacial acetic 
acid and 130 jxl of 0.1% TFA were added to each sample before 
chromatography on a CIS column and elution with a 10-40% 
acetonitrile linear gradient.
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chromatographic profiles changed as the reactions proceeded 
to completion, they never became identical (Figure 14D & E), 
further indicating a difference in substrate specificity.
Amino, Acid Analysis of VIP Cleavage Products 
The initial major cleavage product of the activity of 
each of the tryptase isozymes on VIP was collected and amino 
acid analysis was performed. The results, shown in Table 4, 
suggest that the primary cleavage site for high-HLT is Arg14, 
which agrees with the findings of Tam and Caughey (1990); 
and, although the amino acid analysis results were not as 
clear for low-HLT, the data suggest that the primary 
cleavage site for low-HLT is Arglz. These data correspond to 
fragments of 1-14 for the high-HLT product and 13-28 for the 
low-HLT product. Figure 15 shows the sequence of VIP and 
the proposed cleavage sites for high-HLT and low-HLT.
Attempted Peptide Mapping of the Tryptase Isozymes 
Peptide mapping of the two tryptase isozymes would 
provide some very important information for determining 
whether these isozymes are the gene products of any of the 
cDNAs cloned from human mast cells. Peptide mapping 
involves cleaving a protein at certain points and performing 
limited sequencing of the peptides produced. Peptide 
mapping of the tryptase isozymes was attempted using Lys-C 
(endoproteinase Lys-C from Promega), which cleaves proteins 
on the carboxyl side of Lys residues, and CNBr, which
Table l. Amino Acid Analysis of the Initial Products 86 
Resulting from the cleavage of VIP with High-HLT and Low- 
HLT. The peaks corresponding to the two initial products 
(see Figure 5B and 5C) resulting from the cleavage of VIP 
with each of the tryptase isozymes were hydrolyzed, PITC 
derivatized, and analyzed using the Waters Pico-Tag method. 
An amino acid with a theoretical yield of one was chosen to 
represent an actual yield of one and all other pmol values 
were divided by that pmol value to determine their actual 
yields. The theoretical yields represent VIP residues 1-14 
corresponding to the high-HLT initial product and VIP 
residues 13-28 corresponding to the low-HLT initial product.
Hioh-HLT Initial Peak
Actual Theoretical
ttJBQlqa Yield _ Yield
Asp 32 2.9 3
Glu 2 0.2 0
Ser 18 1.6 1
Gly 4 0.4 0
His 26 2.4 1
Arg 23 2.1 2
Thr 13 1.2 2
Ala 13 1.2 1
Tyr 11 1.0 1
Val 9 0.8 1
Met 1 0.1 0
Cys & lie 6 0.5 0
Leu 13 1.2 1
Phe 10 0.9 1
Lys 1 0.1 0
Table 1. Amino Acid Analysis of the Initial Products 87 
Resulting from the cleavage of VIP with High-HLT and Low- 
HLT. (Continued)
Low-HLT Initial Peak 
Actual 
p moles Yield
Theoretical
Yield
Asp 26 3.7 2
GlU 6 0.9 1
Ser 4 0.6 1
Gly 2 0.3 0
His 2 0.3 0
Arg 7 1.0 1
Thr 6 0.9 0
Ala 8 1.1 1
Tyr 10 1.4 1
Val 3 0.4 1
Met 4 0.6 1
Cys & lie 8 1.1 1
Leu 15 2.1 3
Phe 2 0.3 0
Lys 15 2.1 3
Low-HLT
H igh-H LT
1 10 12 14 20 25
H 2N-His-Ser-Asp-Aia-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-M et-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-ainide
f ig u r e  15. Sequence o f  V IP  S how ing th e  P roposed  C leavage S ites b y  L ow -H L T  a n d  H ig h -H L T . Results o f  am ino a rid  analysis
that the initial product o f  the cleavage o f  V IP  by  low -H LT w as residues 13-28 and the initial product o f  the cleavage o f  V IP by high-H LT was
residues 1-14.
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chemically severs proteins at Net residues. These means of 
cleavage were chosen to try to compare the two isozymes to 
the amino acid sequences encoded by the a and 0 tryptase 
cDNAs cloned from lung mast cells, which exhibit differences 
in the number of these two amino acids. Several months were 
spent on this set of experiments with no significant 
results. However, it was determined that tryptase is 
apparently resistant to cleavage by Lys-C, as evidenced by a 
lack of decrease in M, of tryptase on SDS-PAGE after 
exposure to Lys-C. Intact tryptase completely disappears on 
SDS-PAGE after exposure to CNBr, but successful 
chromatography of the products on reverse-phase HPLC was 
never achieved. C„ and C,( columns were tried with a variety 
of gradients and two different buffer systems (0.1% 
TFA/acetonitrile buffer system and 6 mM HCl/acetonitrile 
buffer system) without any positive results.
CHAPTER 4 
DISCUSSION
Purification and Separation of the Trvntase Isozvmes
Purification and separation of the tryptases proved to 
be somewhat difficult to achieve. The main problems 
encountered were low yields (an average of 25% total 
recovery of activity) and unequal amounts of the two 
isozymes (about 5 times more high-HLT than low-HLT based on 
protein concentration; about 32 times more high- than low- 
HLT based on number of active sites). Low-HLT was also more 
difficult to purify to homogeneity, nearly always containing 
some low M, contaminants that were difficult to remove and 
frequently containing a very small amount of high-HLT. 
Cetylpyridinium chloride treatment of crude extract greatly 
reduced the viscosity of the extract by precipitating 
mucopolysaccharides and nucleic acids. Chromatography on 
butyl HIC followed by cellulose-phosphate ion exchange 
chromatography produced the highest yields and most 
consistent separation of the isozymes. However, an 
inhibitor column, such as SLPI or ArgIJGlunaprotinin, may 
improve enzyme purity and yield. Elution of high-HLT from 
cellulose-phosphate with heparin suggests that high-HLT has 
a high affinity for heparin, whereas low-HLT required high 
salt for elution, suggestive of low heparin affinity.
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Chromatography of crude extracts on heparin-Sepharose with 
Western blot detection has shown that only high-HLT binds to 
heparin (Burnette-Vick, unpublished data).
Structural characterization of the Isozvmes
Previous preparations of human mast cell tryptase have 
contained two bands in the 29-35 kDa range differing by 2-5 
kDa upon SDS-PAGE. Because gel filtration chromatography of 
these tryptase preparations in the past yielded estimated 
molecular sizes of 135-144 kDa (Schwartz et al., 1981a;
Smith et al., 1984), it was assumed that tryptase was a 
tetramer containing two slightly different active subunits. 
Assuming that tryptase actually exists as a tetramer in 
vivo, separation of the two active forms of tryptase implies 
that the tetramer is composed of homologous subunits, rather 
than a mixture of the two bands seen on SDS-PAGE. Gel 
filtration of the two forms of tryptase separated in this 
lab has indicated that high-HLT probably exists as a 
tetramer (approximate M, of 125 kDa) whereas low-HLT may 
exist as a monomer (approximate M, of 28 kDa).
Low-HLT appears to have a lower affinity for heparin, 
relative to high-HLT, providing additional evidence of 
structural differences in the two forms. Rat tryptase does 
not bind heparin (Braganza and Simmons, 1991) and it has 
been shown that mouse tryptase also lacks this affinity 
(Johnson and Burnette-Vick, unpublished data). Heparin
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binding motifs with the sequences BBXB and BBXXB have been 
noted (where B is Lys or Arg; Blankenship et al.f 1990) and 
it has hypothesized that R^-V-R^-D-R13 represents a new 
heparin binding motif of the sequence BXBXB (D. Johnson, 
unpublished data). This sequence is found in HST-3 and HLT- 
a, but is missing from HST-l and HLT-0/HST-2 (Figure 16).
Molecular modeling of the tryptases has shown the 
presence of two insertions not present in trypsin, one on 
either side of the active site (Figure 17), that may 
restrict access to the active site by bulky substrates or 
inhibitors, while allowing small molecules or loop 
structures to reach the active site (Johnson and Barton, 
1992). Figure 17A shows a space filling model of human skin 
tryptase 1 with the two insertions shown in orange and red 
and the active site Ser and His in green and yellow, 
respectively. Another angle of this molecule is shown in 
Figure 17B which exposes the Asp residue at the bottom of 
the S, substrate binding pocket. This may explain in large 
part the high degree of substrate specificity and resistance 
to most inhibitors displayed by the tryptases. This 
information will be useful in future investigations of the 
interaction of tryptase with inhibitors such as SLPI and 
substrates such as HMWK and VIP.
Another interesting observation was that there was a 
difference between the two isozymes in their migration out
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1 11 21 31 Heparin
I ! ! !  Binding
HST-1 IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGG ?
HST-2/HLT-0 IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGG ?
HST-3 IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGG ?
HLT-a IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGG ?
DMCT IVGGREAPGSKWPWQVSLRLKGQYWRHICGG ?
MMCT-l IVGGHEASESKWPWQVSLRFKLNYWIHFCGG No
MMCT-2 IVGGQEAHGNKWPWQVSLRAndtYWMHFCGG No
Trypsin IVGGYTCGANTVPYQVSLN SGY HFCGG No
Chymotrypsin IVNGEEAVPGSWPWQVSLQDKTGF HFCGG No
Figure 16. Amino terminal sequence alignment of the mast 
cell tryptases showing the sequences of the tryptases in 
comparison to those of trypsin and chymotrypsin. HST-1, 
human skin tryptase 1; HST-2/HLT-0, human skin tryptase 
2/human lung tryptase beta; HST3, human skin tryptase 3, 
HLT-a, human lung tryptase alpha; MMCT-l, mouse mast cell 
tryptase 1; MMCT-2, mouse mast cell tryptase 2; DMCT, dog 
mast cell tryptase; trypsin, bovine trypsin, chymotrypsin, 
bovine chymotrypsin. The arginine and lysine residues of 
the potential heparin binding motif site are in bold print. 
The putative Asn-1inked glycosylation site in MMCT-2 is in 
bold lower case print.
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Figure 17 A. Space filling model of HST-1 (Johnson and 
Barton, 1992) constructed on the crystal structure 
coordinates of trypsin. The active site Ser is colored 
green and the active site His residue is yellow. The 
smaller insertion of four amino acids (residues 20 through 
26) is colored orange and the larger insertion (residues 164 
through 174) is colored deep red. Also, the proline-rich 
hydrophobic region of tryptase (residues 139 through 145) is 
colored purple. The nitrogen of the putative Asn-linked 
glycosylation site (residue 203) is colored blue/green and 
is just visible at the top of the model.
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Figure 17 B. Another view of the space filling model of 
human skin tryptase 1 with insertion loops colored orange 
(20-26) and deep red (164-174) as in Figure 17 A. This view 
shows Asp 188 at the bottom of the S, substrate binding 
pocket colored dark purple. The active site Ser and His 
residues are green and yellow, respectively. The proline- 
rich region and the Asn glycosylation site are colored 
purple and blue/green, respectively, as in Figure 17 A.
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of gels onto PVDF and nitrocellulose blotting membranes.
The reason underlying this difference has not been 
elucidated, but suggests further structural differences. 
Isoelectric focusing studies on the enzymes might produce 
data pertinent to this discrepancy.
Vanderslice et al. (1990) presented evidence supporting 
the existence of multiple tryptase genes, and it is possible 
that high-HLT and low-HLT correspond to the gene products of 
the two tryptase sequences that have been derived from human 
lung cDNAs, tryptase-a and tryptase-j3 (Miller et al., 1989 
and 1990). Tryptase-a is 244 amino acids in length with two 
putative glycosylation sites per subunit, whereas tryptase-j3 
is 245 amino acids in length with only one putative 
glycosylation site. Since tryptase-a with two glycosylation 
sites would probably have a higher M, than tryptase-/S, high- 
HLT may correspond to a while low-HLT may correspond to 0. 
Confirmation of this must await further structural 
characterization of the two isozymes.
Functional Differences of the Trvotase Isozvmes
It has been previously reported that the activity of 
human tryptase is dependent on its interaction with heparin 
(Smith et al., 1984; Schwartz et al., 1990). However, if, 
as preliminary data suggest, low-HLT exists as a monomer and 
has a low affinity for heparin, its activity may be 
regulated in an entirely different manner from high-HLT. No
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endogenous inhibitors of tryptase have been reported; 
therefore, a number of trypsin inhibitors were tested for 
activity against tryptase. The inhibitors tested differed 
with respect to size, source and PI amino acid residue, 
which makes elucidation of the characteristic(s) responsible 
for tryptase inhibition more difficult. None of the 
inhibitors with an Arg residue in the active site inhibited 
tryptase, whereas SLPI, which contains a Leu in the active 
site, inhibited both tryptase isozymes.
All of the inhibitors tested are known to inhibit 
trypsin and some are known to inhibit other proteases as 
well. Ecotin, a trypsin inhibitor isolated from E. coll, 
contains 142 amino acids, has a subunit MW of 17 kDa and is 
active as a dimer (McGrath et al., 1991). In addition to 
trypsin, ecotin also inhibits chymotrypsin and neutrophil 
elastase, with Met*4 in the PI position of the inhibitory 
site (McGrath et al., 1991). This active site residue is 
somewhat unusual for trypBin and elastase inhibitors, which 
normally have Lys or Arg and Leu or Val, respectively, in 
their active site (McGrath et al., 1991). However, a,- 
proteinase inhibitor, a plasma protein that inhibits 
neutrophil elastase, has a Met in its active site and also 
inhibits trypsin and chymotrypsin (Johnson and Travis,
1978), but does not inhibit tryptase.
SLPI is a monomeric protein containing 107 amino acid 
residues with a MW of 11,726 Da. It is found in various
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mucous-containing body fluids and also exhibits strong 
inhibitory effects on several proteases, including bovine 
trypsin and chymotrypsin, leukocyte elastase, cathepsin G, 
and chymase (Fritz, 1988; Van-Seuningen and Davril, 1991). 
Its activity against porcine trypsin, however, is reduced 
compared to bovine trypsin (Smith and Johnson, 1985). The 
active inhibitory site has been determined to be Leu73 for 
all proteases that interact with it (Eisenberg et al., 1990; 
Van-Seuningen and Davril, 1991), similar to the peculiar 
inhibitory activity of ecotin.
ASTI is isolated from the porcine roundworm Ascaris 
suum and has a MW of 6880 Da (Peanasky et al., 1987). APPI 
is part of the Alzheimer's amyloid 0-protein precursor and 
blocks proteases that cleave at basic residues (Hynes et 
al., 1990). It has a MW of 6416 Da, is 58 amino acids in 
length, with an Arg,J P, active site (Hynes et al., 1990).
Ial is a large protein complex found in human plasma 
that is made up of three chains— two heavy chains of 
approximately MW 66 kDa each, designated as subunits 0 and 
7 , and a light (a) chain of MW 46 kDa that contains the 
inhibitory activity (Gebhard et al., 1990; Potempa et al., 
1989; Salier, 1990). The light chain, also known as bikunin 
or HI30, has two active inhibitory sites, one with a PI Arg 
and one with a PI Met, and inhibits trypsin, chymotrypsin, 
neutrophil elastase, plasmin, and acrosin (Potempa et al., 
1989; Salier, 1990). The function of the 0 and 7 subunits
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is unknown (Gebhard et al., 1990).
CMTI-III is a 29 amino acid protein of MW 3268 Da that 
is found in pumpkin (Curcurbita maxima) seed extracts 
(Hojima et al., 1982; McWherter et al., 1989). It has an 
Arg in the active site and inhibits Hageman factor fraction 
(jff-factor Xlla) and bovine trypsin (Hojima et al., 1982).
Recombinant Argl5Glu3Iaprotinin is a genetically modified 
form of aprotinin (Auerswald et al., 1988) or bovine 
pancreatic trypsin inhibitor (BPTI), which normally contains 
a Lys at position 15, the PI residue of the active site 
(Scott et al., 1987). BPTI inhibits trypsin, plasmin, 
kallikrein, and chymotrypsin (Auerswald et al., 1988). 
Arg,5GluMaprotinin inhibited human plasmin, bovine a- 
chymotrypsin, porcine pancreatic kallikrein, human plasma 
kallikrein, human urinary kallikrein and human anionic and 
cationic trypsin (Auerswald et al., 1988).
ozM is a large glycoprotein (subunit MW » 180 kDa) that 
usually exists as a tetramer and inhibits a wide range of 
plasma proteinases (Arakawa et al., 1989). The mechanism of 
inhibition by OjM is one of stearic hindrance of the 
proteinase after cleavage of a bait region in the a2M 
molecule by the proteinase which triggers a major 
conformational change and results in the "trapping" of the 
proteinase (Arakawa et al., 1989; Sottrup-Jensen et al., 
1989). The "trapped" proteinase is then inaccessible to 
large substrates but may still interact with very small
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substrates (Sottrup-Jensen et al., 1989).
a^, a rat plasma proteinase inhibitor, is similar to 
djH except that it is a monomer of MW 190 kDa (Lonberg-Holm 
et al., 1987) and has a less efficient trapping mechanism 
that is dependent on the ability of a,I3 to form covalent 
crosslinks with proteinase Lys residues (Enghild et al., 
1989).
The results of the inhibitor assays showed that both 
tryptase isozymes were inhibited by SLPI but were resistant 
to inhibition by all other trypsin inhibitors tested. This 
may be due, at least in part, to specific structural 
characteristics of the isozymes that restrict the activity 
of most inhibitors, such as the loop structures (discussed 
previously) located on either side of the active site.
These data indicate that there may be other endogenous 
inhibitors of tryptase, in addition to heparin, that have 
not been examined.
The two tryptase isozymes were also shown to differ 
with respect to substrate specificity and rate of activity 
on two protein substrates, HMWK and VIP. Although low-HLT 
cleaved HMWK and VIP at 25 and 2 times as fast as high-HLT, 
respectively, low-HLT preparations were only 15% active 
compared with 95% active high-HLT preparations; thus, low- 
HLT appears to be less stable than high-HLT. Low-HLT may, 
however, diffuse through the tissues surrounding the site of 
mast cell degranulation to a much greater extent than high-
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HLT, giving it a broader range of activity. Le Trong et al. 
(1987) presented data suggesting that the specificity of 
chymase may vary according to the presence or absence of 
heparin. Therefore, the difference in substrate specificity 
reported on here may be directly related to the difference 
in affinity for heparin between the two tryptase isozymes.
Our results confirm the reports that HMWK (Maier et 
al., 1983) and VIP (Tam and Caughey, 1990) are substrates 
for human tryptase in vitro and show that both human lung 
tryptase isozymes degrade these substrates. Further, high- 
HLT and low-HLT differ with respect to the rates and the 
primary sites of cleavage on these two natural substrates.
With regard to their activity on HMWK, low-HLT cleaved 
HMWK approximately 25 times as fast as high-HLT, when 
compared on the basis of the number of active sites. In 
addition, high-HLT cleaved HMWK at a single site in the 
light chain, compared with low-HLT, which cleaved the light 
chain into several fragments, similarly, low-HLT cleaved 
VIP approximately twice as fast as high-HLT, with the 
generation of different cleavage products as monitored by 
HPLC. However, the small VIP molecule appears to be a 
better substrate for tryptase than the large HMWK molecule, 
since the E:S ratio required for cleavage was much smaller 
for VIP (1:17,340 based on the number of active sites of 
tryptase) than for HMWK (1:52 with high-HLT and 1:1333 with 
low-HLT). Based on the previously discussed molecular
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modeling studies of tryptase, it has been suggested that 
loop structures adjacent to the active site may provide 
stearic hindrance for larger molecules (substrates or 
inhibitors), making interaction with the active site more 
difficult (Johnson and Barton, 1992).
Attempts to determine the primary cleavage site 
resulting from the activity of each isozyme on HMWK were 
partially successful. High-HLT produced only two major 
cleavage products of 65 kDa and 46 kDa. Limited amino- 
terminal sequencing of the 46 kDa fragment showed that the 
major cleavage site is immediately carboxyl to Arg43l, which 
is in the histidine-glycine-rich procoagulant region of the 
light chain of HMWK* This supports previous reports that 
tryptase destroys the ability of HMWK to participate in the 
coagulation cascade (Maier et al., 1983} and the cleavage 
site is within the recently identified Zn+1 binding region 
of HMWK (DeLa Cadena and Colman, 1992) which is in domain 5 
containing the anionic surface binding subdomain (Kunapuli 
et al., 1993). A predicted secondary structure of the light 
chain of HMWK by Lottspeich et al. (1985) shows this region 
of the molecule as a large loop made up of random coil, 
which is additional evidence for the availability of sites 
in this region to proteolytic cleavage. Low-HLT produced 
cleavage products of M, 75 kDa and 65 kDa, but lacked the 46 
kDa fragment produced by high-HLT. Western blotting with 
antibodies specific for the C-terminal (light chain) region
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of HMWK reacted with only the 46 kDa fragment produced by 
high-HLT and with several smaller fragments produced by low- 
HLT. Attempts to sequence the two low-HLT generated 
fragments of Mr 75 kDa and 65 kDa were unsuccessful, 
presumably due to the blocked amino terminus of HMWK. This 
suggests that these two fragments contain the original amino 
terminus of the molecule. Because low-HLT simultaneously 
cleaved HMWK at several positions in the C-terminal region, 
location of these cleavage positions was not possible.
As previously discussed, prostromelysin (also called 
pro-matrix metalloproteinase-3, MMP-3) has also been 
reported as a tryptase substrate (Gruber et al., 1988 and 
1989). Tryptase presumably cleaved proMMP-3 to MMP-3 which 
then cleaved procollagenase to collagenase. However, 
preliminary data resulting from a collaboration with H. 
Nagase (Univ. of Kansas, Lawrence, KS) has indicated that 
high-HLT does not cleave proMMP-3, but that low-HLT does.
In addition, a collaboration with 5. Stack (Duke Univ., 
Durham, NC) has produced data indicating that high-HLT 
cleaves plasminogen activator and plasmin. Plasmin is 
involved in the dissolution of blood clots by breaking down 
fibrin, the major constituent of clots. The events leading 
to clot breakdown involve activation of single-chain 
plasminogen activator to two-chain plasminogen activator, 
which converts plasminogen to plasmin. Plasmin has the 
capability of activating more plasminogen activator in a
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feedback amplification. High-HLT has now been shown to 
produce plasmin both directly by cleaving plasminogen to 
plasmin and indirectly by cleaving single-chain plasminogen 
activator to produce two-chain plasminogen activator in 
vitro. These data suggest a possible role of tryptase in 
clot dissolution in addition to its potential role in 
anticoagulation. However, the in vivo significance of these 
reactions is unclear.
Taken together these findings clearly demonstrate that 
there are at least two distinct tryptase isozymes in human 
lung tissue that differ in reaction rate and cleavage site 
specificity with two natural substrates. As presented 
above, there is also evidence that they may differ in 
several other respects, such as heparin binding and 
quaternary structure. The implications of these data 
include possible differences in primary structure, radius of 
activity and physiological substrates (function), 
regulation, carbohydrate content, and even secondary and 
tertiary structure. This view differs from the generally 
accepted hypothesis that tryptase exists only as a 
heterotetramer in association with heparin, and expands the 
study of tryptase to include isozymic forms. A modified 
purification procedure must be used in order to retain low- 
HLT and to separate the isozymes. The possible existence of 
endogenous inhibitors and/or other forms of regulation of 
tryptase other than heparin binding should also be
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investigated further.
The physiological significance of the existence of 
these two tryptase isozymes in vivo is not obvious. Both 
isozymes would presumably have the capability to inactivate 
HMWK and VIP upon release from mast cells. It is still 
unclear, however, whether one isozyme actually has a more 
specific function than the other. There is notable 
variability in the amount of tryptase isolated from lung 
tissue obtained at autopsy, but whether this variability is 
due to individual differences or other variables, such as 
time of death relative to when the tissue was frozen, 
remains to be seen. Both low and high-HLT have been 
observed in all our preparations. It seems likely that 
tryptase is of physiological importance given the ubiquitous 
distribution of mast cells in the body and the large amount 
of tryptase present in all mast cells. Mast cells are also 
known to participate in certain pathological conditions, 
thereby implicating tryptase as a contributing factor in 
these conditions. This points to tryptase as a potential 
target of preventive or therapeutic drug therapy. The 
elucidation of the function(s) and regulation of tryptase 
and the corresponding mechanisms, therefore, has potentially 
important medical benefits.
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The Appendix contains data that was meaningful but not 
of high enough quality to be included in the body of the 
dissertation. These data were included so that people 
continuing the tryptase project in the future would have all 
data resulting from this project in a collective and 
organized form. The data herein are referred to in the body 
of the text and are further explained in the figure legends 
accompanying each figure.
Figure 1. BDS-PAGE (10%) with Reduction of Fools from the 
Dowex and Heparin-Sapharose columns. Lane A, crude lung 
extract (25 fil); Lane B, Dowex flowthrough (25 fil); Lane c, 
Dowex pool after dialysis (25 fil); Lane D, flowthrough from 
heparin-Sepharose column (25^1); Lane E, first activity peak 
from heparin-Sepharose (5 fig); Lane F, second activity peak 
from heparin-Sepharose (5 fig). Samples were TCA 
precipitated and resuspended in sample buffer before 
electrophoresis. The outside lanes contain MW markers: 
phosphorylase B (100 kDa), transferrin (78 kDa), BSA (68 
kDa), igG (50 kDa), carbonic anhydrase (29 kDa), soybean 
trypsin inhibitor (21 kDa), cytochrome c (12.75 kDa), and 
Trasylol (6.5 kDa). Protein was visualized with silver 
stain.
Figure 2. 8DB-PAGE (7%) with Reduction of the Inhibitory 
Effects of otjH and on High-HLT and Trypsin. Lane A,
HMWK (20 fig; 438 pmol) and high-HLT (3.5 pmol of active 
sites); Lane B, HMWK, high-HLT and a2M (3.5 pmol); Lane C, 
HMWK, high-HLT and Cjl3 (3.5 fig); Lane D, HMWK (10 ^g); Lane 
E, HMWK and trypsin (0.88 pmol); Lane F, HMWK, trypsin and 
o2M; Lane G, HMWK, trypsin and c,Ij. The enzyme (high-HLT or 
trypsin) and inhibitor was incubated at RT for 30 minutes 
before addition of HMWK, which was incubated at 37°C for 20 
minutes before TCA precipitation and gel analysis. The MW 
standards in the outside lanes are the same as in Figure 1. 
Protein was visualized with colloidal Coomassie blue.
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Figure 3-A. SDS-PAGE (7%) with Reduction of Laminin, 
Fibrinogen and Fibroneotin after Exposure to High-HLT. Lane 
A, laminin (13.4 fig, 13.4 pmol); Lane B, laminin and high- 
HLT (0.07 pmol); Lane C, fibrinogen (13.4 fig, 39.4 pmol); 
Lane D, fibrinogen and high-HLT (0.20 pmol); Lane E, 
fibroneotin (13.4 fig, 26.8 pmol); Lane F, fibroneotin.and 
high-HLT (0.13 pmol). The E:S ratio in each case was 1:200 
based on protein concentration. MW standards are the same 
as in Figure 1. Proteins were visualized with colloidal 
Coomassie blue.
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Figure 3-B. SDS-PAGE (4-20%) with Reduction of Lauinin, 
Fibrinogen end Fibroneotin after Exposure to High-HLT. This 
gel was a duplicate of Figure 3-A except that half the 
amount of protein was loaded in each lane and the gel was 
developed with silver stain.
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Figure 4-A. SDS-page (10%) with Reduction of the cleavage 
of HMWK by High-HLT Without Precipitation Prior to 
Electrophoresis. Lane A, HMWK at zero minutes (2 fig, 17.8 
pmol); Lane B, HMWK and high-HLT (0.04 pmol) after a 5 
minute incubation at RT; Lane C, 10 minutes; Lane D, after 
20 minutes; Lane E, 40 minutes; Lane F, after 60 minutes; 
Lane G, after 90 minutes. The E:S ratio was 1:50 based on 
protein concentration. MW standards were as in Figure 1 and 
proteins were visualized with silver stain.
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Figure 4-B. BDS-PAQB (10%) with Reduction of the Cleavage 
of HMWK by Lov-HLT Without Precipitation Prior to 
Electrophoresis. This gel was performed as in Figure 4-A 
except that 0.01 pmol of low-HLT was used per sample instead 
of 0.04 pmol of high-HLT and Lane A contained HMWK after 90 
minutes at RT, pH 7.5.
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